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ABSTRACT 
 
Autism is a heterogeneous neurodevelopmental disorder that is characterized by 
impaired social interaction and communication as well as restricted and repetitive 
behaviors and focused interests. In addition to the cardinal behavioral characteristics 
observed for diagnosis, autistic individuals exhibit a number of comorbid conditions as 
well as a variety of aberrant immunological features. Recent studies report that plasma 
from autistic children contained elevated levels of secreted amyloid precursor protein 
alpha (sAPP-α), the α-secretase cleavage product of the amyloid precursor protein (APP) 
which is ubiquitously expressed in the brain, spleen, thymus and other organs. 
Interestingly, the sAPP-α fragment functions as a neurotrophic and neuroprotective 
factor in the central nervous system (CNS) and is also implicated in T-lymphocyte 
activation in the periphery. These functions of sAPP-α, alongside the observation of the 
fragment at elevated levels in autism patients, led us to hypothesize that sAPP-α over-
expression is associated with autism and may be involved in its 
pathophysiology by impacting the brain or the immune system, leading to 
autistic-like behavior. In order to determine how the sAPP-α fragment may affect 
autism pathophysiology, we generated transgenic mice that overexpress human sAPP-α 
and used molecular biology, immunohistochemistry and behavioral techniques to study 
them. Additionally, we examined sAPP-α levels in plasma from a unique cohort of autism 
patients, and levels of both sAPP-α and the α-C-terminal fragment (α-CTF) in post 
viii 
 
mortem brains from an unrelated cohort of autistic patients. Resulting data from studies 
on autistic patient tissue samples confirmed the increase in plasma sAPP-α seen in 
autism patients in an earlier study and identified elevations in the sAPP-α and α-CTF 
fragments of post mortem insular cortex brain homogenates from autistic children. Data 
from molecular biology studies on the human sAPP-α transgenic (TgsAPP-α) mice 
demonstrate that these mice mimic the human autistic condition, expressing elevated 
levels of hsAPP-α in both the brain and plasma. They also show increased synaptophysin 
expression, suggesting increased synaptic density, in the brain. Behavior tests showed 
that while they do not display anxiety, lack of motor coordination/balance or impaired 
cognition, TgsAPP-α mice are hypoactive and the males exhibit decreased preference for 
social interaction. Molecular biology, immunohistochemistry and flow cytometry 
experiments focusing on immune function in TgsAPP-α mice unearthed aberrant 
development and function of T-cells. Compared to those from wild-type littermates, 
splenocytes from TgsAPP-α mice consisted of decreased B-cell and increased T-cell 
populations and secreted increased interferon-γ (IFN-γ), interleukin-2 (IL-2) and IL-4 
after T-cell mitogen challenge. We discovered alterations in T-cell and thymocyte 
populations within TgsAPP-α mouse thymi, which may be explained by data portraying 
reduced apoptosis and decreased pro-apoptotic signaling. Finally, the splenocytes from 
TgsAPP-α mice immunized with myelin oligodendrocyte protein displayed impaired recall 
memory function which may be influenced by reduced phosphorylation of δ-chain-
associated protein kinase 70 (ZAP-70), an apparent trait in TgsAPP-α mice irrespective 
of immunization. Altogether, the data leads us to conclude that overexpression of the 
sAPP-α fragment is indeed associated with autism, and sAPP-α overexpression leads to 
hypoactivity and impaired social behavior as well as aberrant T-lymphocyte development 
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and function. For autism, the data implies that sAPP-α overexpression may contribute to 
autism pathophysiology through its effects on the immune system, leading to the 
characteristic behaviors. The data also provides evidence for a likely association 
between sAPP-α over-expression and aberrant T-cell populations and function in autism 
patients. Studies of sAPP-α interaction with the immune system and in the brain at the 
molecular level are needed to further clarify the purpose of sAPP-α overexpression in 
autism patients. 
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CHAPTER 1: INTRODUCTION 
 
Autism Spectrum Disorders 
 Autism spectrum disorders (ASDs) are a range of neurodevelopmental disorders 
that severely affect the quality of life of affected patients and their families. The range 
of disorders includes “classic” autistic disorder, Asperger syndrome, and pervasive 
developmental disorders not otherwise specified (PDD-NOS) [1, 2]. These disorders, 
along with Childhood Disintegrative Disorder and Rett syndrome, are classified as 
pervasive neurodevelopmental disorders [2]. For the purposes of the dissertation, the 
terms “autism spectrum disorders” and “autism” are used interchangeably. Autism 
patient symptoms are very heterogeneous [3], but the disorders are identified by the 
following overarching characteristics: impaired social interaction, deficient verbal and 
non-verbal communication, highly restricted interests and/or stereotypied, repetitive 
behaviors [4, 1, 2]. Autism may also be classified by severity [5]. Since its identification 
in the United States in 1943 by Dr. Leo Kanner [6], scientists and clinicians continue to 
uncover details about autism in order to understand its cause  and develop cures or 
treatments; much has been discovered [7]. 
Autism currently affects 1 in 88, or over 1 million children in the United States, 
and the average worldwide prevalence for children aged 5 – 9 years, based on studies in 
Europe, Asia and North America from 2003 - 2004 is estimated at 1% [8]. The disorder 
is over four times more prevalent in boys than in girls across all races, ethnicities and 
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socioeconomic groups [1, 2] Despite difficulties in obtaining accurate assessments of 
prevalence rates, autism prevalence worldwide continues to increase [9, 10]. These 
increases are commonly attributed to increased awareness of the disorder in the greater 
community and the use of broad diagnostic criteria [11]. What is more, the average 
medical expenditure for a single child with autism in the US is up to 6 times greater than 
that of a non-ASD child, and the lifetime cost of care for a single individual with autism 
was an estimated $3.2 million in the United States [12], with costs of up to $6,200 more 
per year than children without autism for medical expenses [13]. The high cost of 
medical care for patients with autism combined with the rapidly increasing prevalence of 
the disorder create a sense of urgency for an understanding of its pathophysiology, 
leading to effective therapeutics.  
The exact etiology of autism continues to elude scientists and clinicians. It is 
widely accepted that genetics contribute to the disorder, as there is an autism 
recurrence rate of up to 8% in siblings of affected children and a concordance rate of up 
to 92% in monozygotic twins with classic autism [14-17]. Several genes that either 
increase susceptibility or are involved in phenotype have been identified and are being 
studied [18-26]. In fact, while 10 – 20% of autism cases may be attributed to defined 
genetic mutations, genetic syndromes or de novo copy number variants, these genetic 
aberrations individually account for only 1 – 2% of ASD cases [11]. This strongly 
suggests, therefore, that genetics do not account for the vast phenotypic variation 
observed in autism patients [27] and environmental factors are likely to interact with an 
underlying genetic profile [28, 29]. Although autism is the most heritable of all the 
neurodevelopmental disorders, a recent study involving twin pairs with at least one twin 
diagnosed as autistic suggests that ASD liability is only moderately dependent on genetic 
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heritability and that a shared environment makes a substantial contribution [30].  In 
addition, the majority of autism cases have no known genetic cause. This indicates that 
environmental factors such as maternal immune activation and toxins such as lead and 
mercury [31], thalidomide and certain viral infections [32] contribute to the etiology of 
autism. Identification of environmental factors remains controversial. For example, the 
ethyl-mercury ingredient of vaccines, thimerosal, once thought to contribute to autism 
etiology has been disproven as a causative agent [33]. In addition, the bowel is 
considered a pathogenic agent of autism, particularly through the effects of exogenous 
opioids and multiple viral infections [34-37]. 
Given that no single cause for autism has been identified, there is justifiably no 
single medicinal cure for the disorder. Indeed, there may be no single therapeutic 
approach for autism spectrum disorders in the future, and subsets of patients with 
similar phenotype may require individualized treatments. In the mean time, parents and 
clinicians employ either one or combinations of four types of treatment for autism 
patients: 1. behavioral and communication approaches such as Applied Behavioral 
Analysis; 2. dietary approaches like gluten/casein free diets; 3. medicine for specific,  
related symptoms and co-morbidities, such as Risperidone for aggression; and 4. 
complementary and alternative medicine like chelation, or secretin administration [1]. 
Furthermore, there is currently no biomedical method of diagnosis for autism [38, 
39]. Clinicians observe behaviors and development to diagnose the disorder in 
accordance with criteria described in the Diagnostic and Statistical Manual of Mental 
Disorders [4, 40]. Behavioral tools include the Autism Diagnostic Interview-Revised (ADI-
R) and the Autism Diagnostic Observation Schedule (ADOS) [41]. Reliable diagnoses can 
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be made in children as early as at 2 years of age, however final diagnoses usually occur 
later in a child’s life.  
 
Neurobiological Features of Autism 
 Several neuropathologies found in various brain regions that are unique to ASD, 
as compared to the brains of typically developed controls and/or patients with other 
developmental disorders. These pathological features have been identified from studies 
of post mortem brains of autistic individuals as well as magnetic resonance images 
(MRIs) of patient brains. All autism brains do not exhibit the same neurobiological 
features and thus the characteristic heterogeneity of the disorder extends to 
neuropathology as well [42]. 
One feature, macrocephaly, for example, is not present in most cases at birth 
but occurs in up to 20% of autistic child and adult sample populations, based on head 
circumference measurements [43-49]. Cerebral volumes of ASD children aged 3 – 4 
years were significantly increased compared to typically developed and developmentally 
delayed children in the same age bracket [50] and in some patient cases there is 
evidence of an altered gray/white matter ratio [51]. In fact, many MRI studies of brain 
volumes in autistic patients identify increases in autistic patients, compared to controls 
[52-55, 49], and studies of post mortem brain weights are consistent with these findings, 
showing increases in ASD patients as well  [54, 45, 56-58].  On the contrary, there are 
cases of microcephaly in 15% of autism patient sample populations [48] and the size of 
the brainstem and cerebellum in some autistic patients is smaller than those found in 
typically developing controls [59].  
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Structural irregularities in the cerebral cortex of autism patients are commonly 
identified. As an example, areas of cortical abnormalities were identified in four out of 
six autism patients [45]. However, brain abnormalities identified post mortem are not 
limited to the cortex and include: reduced neuron cell size and increased packing density 
in the amygdala, entorhinal cortex, subiculum, mammillary bodies, septum and 
cerebellum [60-65]; dendritic abnormalities in the CA1 and CA4 hippocampal regions 
[66]; polymicrogyria, macrogyria, and schizencephaly [55], which hint at disturbances in 
cell migration during corticogenesis [67]. Further, both the hippocampus and the 
amygdala are enlarged in autistic patients, though amygdala enlargement was limited to 
younger autistic patients [68]. On the other hand, cerebellar vermis volumes are 
reduced in children with autism [69]. There is evidence of enlarged neurons in 
abundance in the vertical limb of the diagonal band of broca, cerebellar nuclei and 
inferior olive of younger autistic subjects, with fewer, smaller, paler neurons in those 
areas of the brains of older autistic subjects [70]. Other studies suggest that there is no 
difference between ASD patients and controls in cortical neuron cell counts [71] or 
neuronal density due to a significant increase in minicolumn numbers with less neurons 
per column [72, 73]. Other evidence from neuropathology studies suggests greater 
neuronal density in the limbic system of ASD patients [74, 57]. However, a recent 
stereology study on a small cohort of autism patients and controls observed a 67% 
increase in the number of neurons in the prefrontal cortex of autism patients [75]. 
Findings of increased neuron density in the amygdala of autism patients led to 
studies on the potential contribution of this brain region to social impairment [76]. 
These studies concluded that the amygdala does not directly impact social behavior but 
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rather functions in threat detection and the appropriate fear response and may therefore 
contribute to the abnormal fears and increase in anxiety seen in autism patients [77, 78].  
Some of these neuropathologies contribute to the hypothesis that there is a 
critical window in the time course of postnatal neurodevelopment during which these 
abnormal pathologies occur, leading to autism in patients [79, 80]. Evidence suggests a 
rapid postnatal acceleration of brain growth during the first 2 years of life, which 
coincides with behavioral symptom onset and may cause increased brain volume in 
autistic patients [81, 54]. The theory continues with the idea of a premature growth 
arrest or slowing that occurs after the overgrowth in cerebral, cerebellar and limbic brain 
areas [82] with the abnormalities in growth being greatest in frontal lobes [83]. Other 
indications for involved mechanisms of abnormal neuropathology include an 
overproduction of neurons or other brain cells, and a lack of synaptic pruning and 
synapse consolidation [79, 84]. These further contribute to the above-described theory 
by providing an explanation for the hypothesis that microstructural maldevelopment and 
distance over-connectivity impairs the essential role of the frontal cortex in information 
integration [85, 86]. It is worth noting that there is no association between head 
circumference and executive dysfunction in autism patients [46]; both are independently 
related to ASD [87]. 
 
Immunologic Symptoms of Autism 
 In addition to the standard behavioral phenotypes observed for diagnosis and 
the anomalous neuroanatomic features identified in autistic brains, autism patients 
present with a diverse range of immunological abnormalities. In the clinic, subsets of 
ASD patients that present with frequent infections that are usually viral, accompanied by 
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worsening behavioral symptoms and/or loss/decrease in acquired skills, have been 
identified [88, 89]. Infection or inflammation during fetal or postnatal development may 
play a role in the pathophysiology of autism [90-92] but other studies report that 
perinatal infection does not necessarily suggest cause [93] and that abnormal immune 
function is present in a minority of autistic children [94].  
Despite opposing conclusions on the role of the immune system on autism 
pathogenesis, several studies describe ongoing immune dysfunction within the central 
nervous system (CNS) as well as in the peripheral immune system of patients. It is well 
known that cytokines can cross the blood-brain barrier [95] and profoundly affect 
neuronal development, migration, differentiation and synapse formation [96, 97] and 
since cytokines constitute the chief method of communication within the immune system, 
any irregularity in their concentrations could impact neurodevelopment. Unfavorably, 
many of the immunological features that have been identified in autistic patients are 
inconsistent between study cohorts.  
Dysfunction in the peripheral immune system of autism patients appears in many 
forms but trend towards a pro-inflammatory profile. Scientists have observed elevated 
levels of several pro-inflammatory cytokines such as interferon gamma (IFN-γ), 
interleukin-1 β (IL-1β), IL-6 and tumor necrosis factor α (TNF-α), and others in 
postmortem brains [98-101]. Elevations in these cytokines have also been observed in 
the plasma of child and adult ASD patients [102-105]. Congruently, there are studies 
showing decreased plasma circulation of anti-inflammatory cytokines transforming 
growth factor beta (TGF-β) and IL-10 in ASDs [106-108], supporting the pro-
inflammatory inclination in these patients.  
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 Studies of the cellular immune response demonstrate that the activities of 
populations from both the innate and the adaptive systems differ in ASD patients 
compared to typically-developing children. Peripheral mononuclear blood leukocytes 
(PMBLs) from ASD patients produce altered toll-like receptor (TLR) responses which can 
mediate neuro-immune interactions [88]. Monocytes and natural killer (NK) cells are 
among those that have been more widely studied in the innate system, and results 
present a general reduction in NK cell capability [109-112] and, in contrast, amplified 
numbers and cytokine release responses from monocytes [113]. Lymphoblasts isolated 
from the blood of autistic patients secreted increased levels of TNF-α and IL-6 in culture 
[100]. In the CNS, there is evidence of increased microglial activation in autism patients 
[114].  
Variations in the adaptive response in autism patients, based on the literature, 
are more prominently attributed to the T-lymphocyte, as several studies report unusual 
features of T-lymphocyte population patterns and function that are sometimes 
contradictory. There have been reports of depressed responses of T-lymphocytes to T-
cell mitogens and recall antigens [115], as well as decreased populations of CD3+, CD4+ 
and CD8+ T-cell subsets in autistic patients [116, 109, 117-122]. Individuals with ASD 
have a prevalence of circulating CD4+ and CD8+ T-cells containing elevated intracellular 
levels of IL-4 but reduced levels of IFN-γ and IL-2 [123]. A lower percentage of T-
lymphocytes expressing the IL-2 receptor after phytohemagglutinin (PHA) stimulation 
was also observed in autism patient plasma [118]. These data suggest a shift towards 
the T-helper cell 2 (TH2) versus the TH1 response. Differences in activation of circulating 
T-lymphocytes are observed in ASD individuals, as patterns of expression of markers of 
activation, on CD3+, CD8+ T-cells for example, are varied [124, 105]. On the contrary, 
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other studies looking at the proportions of CD3+, CD4+ and CD8+ T-cells in children with 
autism compared to normally developing children have shown that there are no 
significant differences between these two groups in these T-cell populations in either 
stimulated or unstimulated conditions [125, 126]. 
Although circulating B-cell numbers and proportions appear normal in autism 
patients [116], the humoral immune response of these patients is also affected. Studies 
report decreases in total levels of IgG and IgM antibody classes that correlate with 
symptomatic ASD behavior [127], and unusual antibody autoreactivity towards brain and 
CNS proteins such as myelin basic protein (MBP), serotonin receptors, and glial filament 
proteins [128-131]. Some ASD patient subpopulations demonstrated elevations of IgE 
levels [116] and still others exhibited greater frequencies of serum antibodies against 
brain endothelial cells and nuclei [132]. In addition to autoantibodies within autistic 
children [133], circulating maternal antibodies against fetal brain antigens are present 
during prenatal development [134, 135]. 
In addition to reports of autistic children with strong family histories of 
autoimmune disorders [136], many of the observations of the peripheral immune system 
in autistic patients have led scientists and clinicians to think that autism may be an 
autoimmune disorder [103]. Findings include increases in anti-brain autoantibodies, as 
previously mentioned, as well as an association with autoimmune enteropathies [37] 
and decreases in activated lymphocytes with increasing age [126]. Any of these 
immunity anomalies can adversely affect child brain development and may contribute to 
autism pathophysiology. 
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Current Mouse Models of Autism 
 Animal models of autism are consistently being developed based on generally 
accepted genetic and environmental factors, believed to contribute to the disorder, that 
have been identified in the ASD patient population. Systematic behavioral, 
neuroanatomical and physiological studies are carried out on these animals, and their 
validity is based on how closely these characteristics line up with the symptoms 
observed in patients. Mice are most often used, but models have also been designed in 
rats, guinea pigs and prairie voles [137-139]. Assays that determine autistic behavior in 
models measure animal-oriented features of the three defining characteristics of the 
disorder: impaired social interaction, deficient communication and repetitive behaviors 
[140]. Studies also identify neuroanatomy and neurochemistry in these models that 
mimic observations in autism patients [141]. 
Genetic bases for models focus on common gene mutations that are found in 
subsets of autism patients, (monogenic syndromes) such as the FMR1 knockout mouse 
[142], based on Fragile-X syndrome, the TSC1 mutant mice for tuberous sclerosis [143], 
and the MECP2 knockout mouse for Rett’s syndrome [144] for example. Some knockout 
mice look at autism susceptibility genes, so called because the presence of mutations in 
these genes are believed to also be involved in autism pathophysiology. These include 
the CNTNP2, NLGN 3 and 4, NRXN 4, and the EN2  knockout mice [145-147, 21, 22, 148, 
149].  
Models based on potential environmental causes look at inflammation and toxins 
that are commonly affiliated with autism development. The maternal immune activation 
(MIA) model is one in which inflammation is induced in a pregnant dam using poly I:C, 
influenza or LPS to produce behaviorally deficient offspring [150-152]. There are also 
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models based on thimerosal exposure [153]. The valproic acid model is similar to the 
MIA model in that pregnant dams are treated with valproic acid and the offspring are 
studied for autistic-like features [154-156, 138].  
Manipulated secretion of neuropeptides such as oxytocin [157-159], vasoactive 
intestinal peptide [160, 161] and vasopressin [162, 137, 163, 164] and 
neurotransmitters like serotonin  have also produced models that primarily exhibit 
altered social behaviors as well as neurochemical and brain structural changes 
consistent with autism [165, 166]. Models of autism have also emerged in the BTBR and 
BALB/c mouse strains which, when compared to other mouse strains, exhibit both 
behavioral and neuroanatomic (in the case of the BTBR mouse [167]) features of autism 
[168-170, 142]. 
 
Secreted Amyloid Precursor Protein Alpha (sAPP-α) 
 The secreted amyloid precursor protein alpha (sAPP-α) fragment has been found 
at elevated levels in children with autism [171-173]. The fragment is derived from the 
amyloid precursor protein (APP), which is a ubiquitously expressed single-pass 
transmembrane protein found in many types of mammalian cells and plays key roles in 
the development and function of the CNS and the immune system [174]. APP is 
expressed as different isoforms [175-177], which arise as a result of alternative splicing 
of its pre-mRNA. The most commonly identified isoforms are APP770, APP751 and 
APP695, named for the numbers of constituent amino acids. APP695 is expressed most 
predominantly in neurons [176], while APP770 is more prevalent in glial and immune 
cells [178].  
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 APP is processed via two main pathways: the amyloidogenic and the non-
amyloidogenic pathway. In the amyloidogenic pathway, APP is first cleaved by a beta 
secretase (β-secretase) enzyme, followed by a gamma secretase (γ-secretase) enzyme. 
This produces secreted amyloid precursor protein beta (sAPP-β), and the amyloid beta 
(Aβ) fragment which is the primary component of the extracellular plaques characteristic 
of Alzheimer’s disease brain pathology [179]. The non-amyloidogenic pathway, however, 
occurs when APP is first cleaved by an α-secretase enzyme, followed by the γ-secretase 
enzyme. The sAPP-α fragment is produced immediately after α-cleavage which occurs at 
the cell surface in neurons [180] and likely in other cells. It is a large fragment, and 
since the majority of the fragment is located extracellularly, it is “secreted” into the 
extracellular matrix [181]. Cleavage of the neuron-specific isoform of APP occurs 
between amino acid residues Lys613 and Leu614 and produces a fragment that is 612 
residues long [174]. Given that the non-amyloidogenic pathway occurs 90% of the time 
in neurons, sAPP-α is constitutively released [182].  Studies suggest that sAPP-α may 
also be released in an activity-dependent manner [183, 184, 181].  
 The sAPP-α fragment possesses neurotrophic and neuroprotective properties. 
Saitoh et. al. showed that sAPP-α regulated the growth of fibroblasts, giving the first 
hint of trophic capabilities for the fragment [185]. Later studies in neurons 
demonstrated that sAPP-α regulates neurite growth, differentiation and survival as well 
as excitability and synaptic plasticity [186-200]. Development and synaptic plasticity in 
the nervous system may be regulated by sAPP-α through modulation of neuronal 
excitability [201]. The fragment potentiated the transdifferentiation of bone marrow-
derived adult progenitor cells into neural progenitor cells which terminally differentiated 
into a cholinergic-like neuronal phenotype [202]. Other studies showed sAPP-α 
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protecting neurons from damage and death by reducing and preventing high 
intracellular calcium concentrations [203], increasing neuronal calcium excitotoxicity 
threshold [189] weakening glutamate-induced intracellular calcium increase [204], 
preventing Aβ-induced oxidative injury [203, 205], reducing caspase 3 mediated 
apotosis in neurons after traumatic brain injury [206] and antagonizing proteasomal-
stress-induced dendrite degeneration and neuronal cell death [207]. Moreover, the 
release of sAPP-α from human SH-SY5Y neuroblastoma cells after treatment with anti-
Parkinson drug analog propargylamine accompanied the reversal of apoptotic effects in 
these cells, supporting the association of sAPP-α with neuroprotective activity [208, 209].  
Efforts to shed light on a mechanism for the neurotrophic effects of sAPP-α 
revealed that neuroprotective effects against glucose deprivation and glutamate toxicity 
may be mediated by increased cyclic guanosine monophosphate (GMP) levels leading to 
the reduced intracellular calcium levels previously mentioned [210]. Stimulation of brain 
membrane preparations by sAPP-α led to dose-dependent increases in cGMP formation, 
which suggests that sAPP-α acts through a membrane-associated guanylate cyclase 
[211]. Another study shows that sAPP-α prevents excitotoxicity by selectively 
suppressing N-methyl-D-aspartate (NMDA) currents in cultured embryonic rat 
hippocampal neuron cells [212]. Yet another proposed theory by which sAPP-α may 
exert its neurotrophic effect is by direct interaction with its parent protein, APP. 
According to this theory, sAPP-α disrupts the dimerization of APP at the cell membrane, 
thereby protecting neuroblastoma cells from cell death [213]. Studies also suggest that 
sAPP-α may exert its activity through MAPK [214], phosphoinositide protein kinase C 
[215], nerve growth factor/insulin [216]. 
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Interestingly, evidence suggests that sAPP-α may work in conjunction with other 
neurotrophic factors to potentiate their effects or as part of a mechanism of its own 
function. For example, sAPP-α requires the insulin growth factor pathway, used by 
neurotrophic factor insulin-like growth factor 1 (IGF-1) [217], for its neuritotrophic 
function [218]. However, sAPP-α acts synergistically with low levels of nerve growth 
factor (NGF) to stimulate neurite outgrowth in PC12 neuronal cells, making them more 
responsive through an independent pathway [219]. 
 Other brain cells are affected by the sAPP-α fragment. Adult hippocampal neuron 
progenitor cells proliferate and are steered towards a glial cell fate after treatment with 
sAPP-α in vitro [220]. Microglia can also be activated by sAPP-α and, in response, 
release toxic levels of glutamate which can lead to neuronal death and synaptic 
degeneration [221]. Treatment of microglia with sAPP-α resulted in increased markers of 
inflammation and neurotoxin production which was attenuated [222]. 
 In addition to its functions within the brain, evidence suggests that sAPP-α is 
involved in the initiation of the T-lymphocyte response. APP is a surface molecule of T-
lymphocytes in the human spleen, and sAPP-α release appears to increase after T-cell 
stimulation [223]. Transcription, translation and secretion of APP were induced upon 
stimulation of peripheral mononuclear blood leukocytes (PMBLs) with T-cell mitogens 
[224]. Moreover, secreted APP is expressed by CD4+ and CD8+ T-lymphocytes after 
stimulation with T-cell specific mitogen phytohemagglutinin (PHA), suggesting that sAPP 
is involved in the initiation of the T-cell mediated immune response [225]. Also, human 
peripheral T-cells, as well as Jurkat cells, expressed increased levels of APP mRNA 
expression when activated with a calcium ionophore [226]. APP appears to mediate 
monocyte pro-inflammatory activation by way of integrin-dependent adhesion and 
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interaction with tyrosine phosphorylated proteins [227]. To widen the scope of 
association even further, weak expression of APP on the cell surface of human 
lymphocytes and monocytes at rest was strengthened after stimulation with a variety of 
immune cell activators [228]. Considering the roles played by sAPP-α in immune 
cells,elevated levels of sAPP-α in the periphery, as demonstrated by the above 
mentioned group of autistic children, must have some effect on the immune response. 
The immune abnormalities present in the relevant subset of autism patients may be a 
consequence or a cause of exposure to excess sAPP-α. Also in the periphery, sAPP-α is 
secreted by platelets and appears to be a ligand for the class A scavenger receptor 
which is expressed on macrophages and binds to lipoproteins [229]. 
The following chapters of this dissertation present data generated from human 
and mouse samples that support the previously identified notion of an association 
between the sAPP-α fragment and autism spectrum disorders and depict the means by 
which elevated levels of sAPP-α may impact autism pathophysiology through 
neurological and immunologic functions.  
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CHAPTER 2: MATERIALS AND METHODS 
 
Human Brain Tissue Samples and Preparation 
Postmortem specimens from the insular cortex brain region of 8 normally 
developed controls and 6 autism patients were acquired from the National Institute of 
Child Health and Human Development Brain and Tissue Bank (NICHD, University of 
Maryland, Baltimore, MD) through the Autism Tissue Program.  Approval for study 
involving these specimens was granted by the institutional review board of the 
University of South Florida Morsani College of Medicine.  Autism diagnoses were 
determined using the Autism Diagnostic Interview - Revised (ADI-R).  Mean ages (years 
± SD) at time of death for control and autism patients were 7.2 ± 2.7 and 7.4 ± 2.4 
respectively.  Mean post-mortem intervals (hours ± SD) for control and autism patients 
were 18 ± 9 and 19 ± 10 respectively. Frozen samples of human brain tissue were 
homogenized in 1X RIPA buffer (Cell Signaling, Boston, MA) with 1% PMSF, centrifuged 
at 14,000 rpm for 90 min at 4˚C before storage at -80˚C. Before use, samples were 
centrifuged at 14,000 rpm for 2 h at 4˚C.  
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Mice 
Generation and Genotyping 
Generation of TgsAPP-α mice was carried out at the H. Lee Moffitt Cancer Center 
Animal Core Facility (Tampa, FL, USA) by standard pronuclear injection. A 1.8-kb 
genomic fragment transcribing hsAPP-α695 was subcloned into a Mo-PrP.Xho vector [230, 
231]. The pcDNA3.1 plasmid containing the hsAPP-α695 DNA fragment was graciously 
provided by Dr. Steven Barger (University of Arkansas, Little Rock, AR, USA). Several 
lines of TgsAPP-α mice were generated, and the line with the highest level of hsAPP-α 
protein expression was selected and maintained by heterozygous backcrossing on the 
C57BL6 mouse strain. Animals were genotyped by quantitative real-time PCR using the 
following sequences of primers:  
hsAPP-α forward, 5’-GCCTGGACGATCTCCAGC-3’;  
hsAPP-α reverse, 5’-TGGCCCGGTGTTAGCACTGGC-3’;  
β-actin forward, 5’-AGCTTGCTGTATTCCCCTCCATCGTG-3’;  
β-actin reverse, 5’-AATTCGGATGGCTACGTACATGGCTG-3’.  
 
Housing and Maintenance 
Mice were housed in animal facilities (Morsani College of Medicine and Byrd 
Alzheimer’s Institute) at the University of South Florida (USF) under a 12-h light-dark 
cycle. Food and water were provided ad libitum. All experiments were conducted in 
compliance with institutional guidelines and in accordance with protocols approved by 
the USF Institutional Animal Care and Use Committee. 
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MOG Immunization 
Mouse myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 was obtained 
from Mimotopes Peptide Company, Raleigh, NC. On Day 0, male and female transgenic 
mice, 12-14 weeks of age, were immunized subcutaneously (s.c.) with 200μg  of MOG 
p35-55 in 0.1ml of PBS, emulsified in an equal volume of complete Freund’s adjuvant 
(CFA) supplemented with 2mg/ml of mycobacterium tuberculosis H37Ra. Immediately 
following immunization and then 48 hrs later, mice received an intraperitoneal (i.p.) 
injection of 200ng pertussis toxin (PTX).  Individual animals were observed daily and 
clinical scores were assessed as follows: 0 = no clinical disease, 1 = limp tail, 2 = mild 
monoparesis or paraparesis, 3 = severe paraparesis, 4 = paraparesis and/or 
quadraparesis, and 5 = moribund or death. 
 
Mouse Behavior Testing 
Open Field  
Spontaneous locomotor activity and anxiety levels in the mice were assessed in 
an open field consisting of a square arena with plastic walls and floor that is evenly 
illuminated by white light.  Each mouse was placed in the center of the field and allowed 
to explore for 5 minutes.  Tests were recorded on video and analyzed using Ethovision 
video tracking and behavior analysis software (Noldus, Leesburg, VA).  Parameters for 
measurement included ambulation (total distance traveled), rearing, and time spent in 
the center of the chamber. 
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Elevated Plus Maze 
Anxiety was measured using the elevated plus maze (EPM). The EPM consisted 
of two well-lit open arms (35 cm) and two enclosed arms (35 cm) facing each other. 
Each arm was attached to a common center platform (4.5 cm) and the entire device was 
elevated 40 cm off the ground. Each mouse was placed in the center platform and 
allowed to explore for 5 min. Mice were tracked using AnyMaze Tracking Software 
(Stoelting, Wood Dale, IL). 
 
Rotarod 
This test of motor coordination and motor learning was performed by placing 
each mouse on a rotating drum (Ugo Basile, Stoelting, Wood Dale, IL) that accelerated 
from 4 to 40rpms over a 5 minute period.  Each mouse was made to perform this task 4 
times a day for two days with a 30-min interval between each run on the rotating drum.  
There was at least a 24-hour long interval between the last run on day 1 and the first 
run on day 2.  The latency of the mouse to fall from the drum was the measure of 
motor coordination.  Improvement across trials was the measure of motor learning. 
 
Morris Water Maze 
The Morris water maze consisted of a circular 1.2 m diameter pool filled with 
opaque water at room temperature.  Mice were trained to locate a 10 cm diameter, 
white escape platform hidden 2 cm beneath the water level.  Large extra-maze cues 
were positioned around the room. Each mouse was given four trials per day with an 
inter-trial interval of 1 hour for 7 consecutive days. During these trials, the time to find 
the platform (escape latency), the total distance traveled, and the swim speed of the 
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animals were recorded.  Each animal was given a maximum of 60 s to find the platform. 
Mice that failed to find the platform after 60 s were guided to the platform where they 
remained for 30 s. After resting on the platform, mice were towel-dried and placed in a 
cage with a heating pad under 1 side until dry, then returned to the home cage. On 
days 8, mice were subjected to a probe trial in which the platform was removed and the 
animal was given 60 s to search the training pool for the platform.  Spatial learning was 
evaluated as a measure of the amount of time spent in each quadrant and the number 
of times the animal crossed the area where the platform had been during the training 
sessions. 
 
Fear Conditioning 
Cognitive function was measured using the trace cued and contextual fear 
conditioning test in which the mice were placed in a Plexiglass box with a metal grid 
floor for foot shock delivery (Freeze Monitor, San Diego Instruments, San Diego, CA).  
The chamber for scoring novel context and auditory cued fear was a box constructed of 
white plastic with vanilla extract smeared on its walls.  A computer interfaced to a shock 
stimulator and speaker delivered the auditory stimulus (conditioned stimulus, CS) and 
shock (unconditioned stimulus, US).  The auditory stimulus was white noise at 80-dB 
and the shock was a 0.5-mA AC current for 1 second.  On training day, each mouse was 
placed into the conditioning chamber and presented with two CS-US pairings. Each 
pairing was preceded and followed by a 2-min exploration period.  The mice were 
observed every 10 s during the 2 min before the first CS-US pairing and 3 min after the 
last pairing for the presence or absence of freezing.  Twenty-four hours after training, 
subjects were individually removed from their home cages and taken to the original 
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training room for the contextual fear test. Each subject was placed into the training 
context under conditions identical to training day except that the CS and US was not be 
presented. Freezing behavior was scored every 10 s for 3 minutes. On the same day, 24 
h post-training, mice were individually removed from their home cages and taken into 
the original training room with an altered environment (lights off, no white noise, etc.) 
for the cued fear test.  Each subject was placed in a white box (novel context) for 6 min. 
The first 3 min consisted of baseline exploration in the absence of the CS. During the 
next 3 min, the CS tone used in training was presented. The presence or absence of 
freezing was scored every 10 s.   
  
Social Interaction Task 
The test mouse was first placed in the center chamber of a three-chambered 
apparatus and allowed to explore the entire chamber for a 10 minute habituation period 
with the doorways into the two side chambers open.  After habituation, the test mouse 
was enclosed in the center compartment and an unfamiliar mouse of the same strain 
and gender was enclosed in one of two wire cages positioned in each of the side 
chambers.  The location for the stranger mouse was alternated.  Following placement of 
the stranger mouse, the doors were re-opened, and the subject mouse was allowed to 
explore the entire apparatus for a 10-min session with the option to interact with the 
unfamiliar mouse or stay isolated. The entire experiment was recorded on video and the 
Ethovision 3.0 video tracking software (Noldus, Leesburg, VA) was used to take 
measures of the amount of time spent in each chamber and the number of entries into 
each chamber by the automated testing system.  Time spent sniffing each wire cage 
was also measured.   
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Tissue Isolation and Preparation 
Tissue Isolation from Mice 
Mice were anesthetized using gaseous isoflourane. Blood was collected from the 
right ventricle of the heart and immediately placed on ice in tubes containing 0.5 M 
EDTA (BD Biosciences, San Jose, CA, USA). Plasma was removed from blood after 
centrifugation at 3000 rpm for 15 min at 4°C. Animals were then perfused transcardially 
with cold 0.01 M PBS (pH 7.4), and the thymus, spleen, and brain were removed. 
 
Mouse Brain Preparation 
Immediately after isolation, brains were sagittally bisected. Left hemispheres 
were either processed whole or separated into hippocampus, striatum, cerebellum and 
cortex regions. Hemibrains or separated regions were homogenized in 1X lysis buffer 
(Cell Signaling, Boston, MA) with 1% PMSF (Sigma-Aldrich, St. Louis, MO), centrifuged 
at 14,000 rpm for 15 min and stored at -80°C.  Right hemispheres were immediately 
immersed and fixed overnight in 4% paraformaldehyde in PBS and cryoprotected in a 
graded series of 10%, 20% and 30% sucrose solutions, each overnight at 4°C.  Right 
hemibrains were then embedded in Neg50 frozen section medium (Richard-Allan 
Scientific, Kalamazoo, MI), and sectioned sagittally on a Microm HM 550 cryostat 
(Thermo Scientific, Richard-Allan Scientific, Kalamazoo, MI) at 25 μm thickness. Free 
floating sections were preserved in 0.01 M PBS containing 100 mM sodium azide at 4˚C 
or PBS with 30% glycerol and 30% ethylene glycol at -20˚C. 
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Splenocyte/Thymocyte Isolation and Culture 
Mouse spleens were harvested and crushed through 40 μm nylon mesh strainers 
into single cell suspensions with PBS using 5 mL syringe plungers. The cells were 
centrifuged at 400g and 4˚C and the supernatant aspirated before the pellet was 
resuspended in 5mL/spleen of ACK red blood cell (RBC) lysis buffer (Invitrogen, Carlsbad, 
CA) for 4-5 minutes at room temperature. After this, PBS was added at 5 – 6 times the 
volume of lysis buffer to stop the reaction and the cells were centrifuged again at 400g 
and 4˚C. The supernatant was removed and the pellet resuspended in PBS for washing. 
The cells were then centrifuged one more time and were finally resuspended in the 
appropriate buffer for study. Splenocytes were suspended in Dulbecco’s Modified Eagles 
Medium (DMEM, Invitrogen, Grand Island, NY) for culture and treatment. For flow 
cytometry, splenocytes were suspended in flow buffer (see Flow Cytometry section 
below).  
Mouse thymocytes were isolated as described for the spleens with the exception 
that pellets of single cell thymocytes were resuspended in 2mL/thymus of RBC lysis 
buffer. Thymocytes were resuspended in flow buffer (see Flow Cytometry section below) 
for staining and analysis. 
 
Thymus Preparation 
Thymus tissue was immediately fixed by immersion in 4% paraformaldehyde in 
PBS (pH 7.4) for 24 hrs at 4˚C. This was followed by cryoprotection through immersion 
in a graded series of 10%, 20% and 30% sucrose solutions overnight at 4˚C. Thymus 
tissue was embedded in Neg50 or OCR frozen section medium (Richard-Allan Scientific, 
Kalamazoo, MI) and was serially and sagittally sectioned on a Microm HM 550 cryostat 
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(Thermo Scientific, Richard-Allan Scientific, Kalamazoo, MI) at 25μm thickness. Sections 
were stored in 100uM sodium azide (Sigma Aldrich, St. Louis, MO) at 4˚C.  
 
Immunohistochemistry 
Immunohistochemistry was performed on free-floating sections in 24-well plates. 
After three 5-minute washes in PBS, sections were blocked for an hour at room 
temperature with agitation in 5-10% horse serum in PBS (blocking buffer). Sections 
were incubated with the primary antibody overnight at 4°C, washed thrice in PBS, then 
incubated in biotinylated secondary antibody for 1 hour. The avidin-biotin complex (ABC) 
was added to the sections for 30-40 minutes and then 1.4 mM 3-3’-diaminobenzidine 
with 0.03% hydrogen peroxide in PBS was used as the chromagen. This final peroxidase 
reaction was for approximately 3 min. Sections were mounted on Superfrost slides 
(Fisher Scientific) then air-dried overnight. Optional counterstaining with hematoxylin for 
no more than 10 seconds was sometimes performed. Then sections on slides were 
washed and dehydrated by rinsing through two 2-minute changes of 95% ethanol, two 
2-minute changes of 100% ethanol and clearing through three changes of xylene. Slides 
were then coverslipped with Permount (Thermo Fisher Scientific).  
 
Flow Cytometry 
Single cell suspensions of thymocytes/splenocytes were resuspended in cold 
0.01M PBS containing 0.1% sodium azide (NaN3) and 5% fetal bovine serum (FBS) (flow 
buffer) and aliquoted into flow cytometry tubes at a minimum concentration of 1 x 106 
cells/mL. Cell suspensions were incubated for 20 – 40 minutes on ice in low light in 
fluorescently-labeled primary antibodies (and antibody controls) diluted to optimal 
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concentrations based on manufacturers’ recommendations. This was followed by three 
washes and resuspension in flow buffer. Data was acquired using an Accuri C6, or a BD 
LSR II Flow Cytometer (by way of the Morsani College of Medicine Flow Cytometry Core 
Facility). Propidium iodide was used to evaluate cell viability.  
 
Western Blotting 
Left brain halves were dissected to isolate cortical and hippocampal regions. 
Each region was immersed in 1X lysis buffer containing 0.1% protease inhibitor 
phenylmethylsulphonyl fluoride (PMSF), homogenized, and stored at -80˚C. Protein 
concentrations in each homogenate sample were measured using the BCA Protein assay 
kit (Thermo Fisher Scientific), and equal amounts of protein were loaded per sample for 
separation by SDS-PAGE. SDS-PAGE was performed using 10% glycine gels with Tris-
Glycine-SDS buffer (BioRad Laboratories, Hercules, CA). Loaded proteins were then 
transferred electrophoretically onto 0.45 μm nitrocellulose transfer membranes 
(Amersham Biosciences, Piscataway, NJ) in Tris-Glycine buffer (BioRad Laboratories). 
Membranes were blocked for non-specific antibody binding using 5% non-fat dry milk in 
1X Tris Buffered Saline (BioRad Laboratories). Immunoblotting was carried out with 
overnight incubation of the membrane at 4⁰C in the appropriate primary antibody for the 
protein concentration level being measured.  This was followed by washes in ddH2O and 
incubation in the respective host-matching horseradish peroxidase (HRP) secondary 
antibody for 1 hour at room temperature as a tracer. The membranes were then 
developed using Femto chemiluminescence substrate (Thermo Scientific). Blots were re-
probed with a reference mouse anti-actin monoclonal antibody, which allows for 
quantification of total protein by densitometric analysis. Densitometric analysis was 
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performed for all immunoblots using the Fluro-S Multimager with Quantity One software 
(Bio-Rad Laboratories, Hercules, CA). 
 
Antibodies Used 
Immunohistochemistry 
The caspase 3 antibody was generated in rabbit and obtained from Cell Signaling 
(Boston, MA). An FD Apop Kit, acquired from FD Neurotechnologies (Ellicott City, MD) 
was used for TdT-mediated dUTP-biotin nick end labeling (TUNEL). 
 
Flow Cytometry 
The following fluorescence-labeled antibodies were obtained from BD Bioscience, 
San Jose, CA: anti-CD19-APC, anti-CD3-FITC, anti-CD4-PE, anti-CD8-APC Cy7, anti-CD4-
FITC, anti-CD8-PE, anti-CD44-PE Cy7, and anti-CD25-APC. 
 
 
Western Blotting 
The following primary antibodies, all generated in rabbit, were obtained 
from Cell Signaling (Boston, MA): anti-Bcl-2, anti-Bax, anti-caspase 3, anti-
phospho-PI3K, anti-total PI3K, anti-phospho-AKT, anti-total AKT, anti-phospho-
ZAP70, and anti-total ZAP70. Other primary antibodies used that were generated 
in rabbit included anti-NICD and anti-synaptophysin from Abcam (Cambridge, 
MA), anti-Notch from Epitomics (Burlingame, CA), and the polyclonal 369 
antibody graciously provided to us by S. Gandy and H. Steiner. The 6E10 
antibody from Covance Research Products (Emeryville, CA) and the β-actin 
antibody from Sigma-Aldrich (St. Louis, MO) were both generated in mouse. 
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The following horseradish peroxidase-conjugated secondary antibodies 
were used: goat anti-mouse IgG from Cell Signaling; and anti-rabbit IgG (1:5000, 
Thermo Fisher Scientific). 
 
Enzyme-Linked Immunosorbent Assays (ELISAs) 
ELISAs for sAPP- 
For the sAPP ELISA used on autism and control plasma samples (as previously 
described by Olsson [232] with minor changes), a high binding 96-well plate (Nunc, 
Denmark) was coated with monoclonal anti-human N-terminal APP66-81 antibody (22C11 
– Biosource) diluted in 100 μL (1 μg/mL) of carbonate buffer (pH 9.6) and incubated 
overnight at 4°C. The plate was washed five times with PBS-Tween buffer (0.05% 
Tween 20) and blocked with 200 μL of blocking buffer (1% BSA in PBS) for 2 hrs at 
37°C. All samples were analyzed in duplicate. Samples of cell cultured media, plasma 
and brain homogenates were diluted 1:1, 1:4 and 1:10 respectively in Reagent Diluent 
(1% BSA in PBS) and added to each well of the plate. The plate was incubated for 2 hrs 
at 37°C. After 5 time-washing, 100 μL of monoclonal mouse anti-Aβ1-17 antibody (6E10), 
diluted in Reagent Diluent, was added to each well of the plates. Following 2 hour-
incubation at 37°C and 5-time washing, 100 uL of anti-mouse IgG conjugated with HRP 
(1:1,500) was added to each well of the plates. The plates were incubated for 1 hr at 
37°C. Following 5-time washing, 100 μL of substrate solution (Chromogen - TMB) was 
added to each well of the plate and incubated for 20 min at room temp. After incubation, 
50 μL of stop solution (2 N H2SO4) was added to each well of the plate. The optical 
density was determined immediately by a microplate reader at 450 nm. Data was 
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reported as ng/mL of sAPP- in cell cultured media and plasma or as ng of sAPP-/wet 
g of brain homogenates.  
Human sAPP-α expression in human and mouse brain homogenates as well as 
mouse plasma was quantified using a highly-specific assay kit (IBL-America, Minneapolis, 
MN).  Using high-affinity 96-well plates (Nunc, Denmark), levels of sAPP-α were 
measured for each human brain sample and each mouse brain and plasma sample in 
duplicate, according to manufacturer’s instructions. 
 
ELISAs for Cytokines 
Duoset and eBioscience ELISA kits provided the reagents to be used for this 
method. High binding 96-well plates (Nunc, Denmark) were coated with a cytokine-
specific capture antibody diluted in phosphate buffered saline (pH 7.4) and incubated 
overnight at 4°C. The plate was washed five times with PBS-Tween buffer (0.05% 
Tween 20) and blocked with 200 μL of blocking buffer (stipulated by manufacturer) for 2 
hrs at room temperature. Samples of cell cultured media, plasma and/or brain 
homogenates were diluted in Reagent Diluent (1% BSA in PBS) and added to each well 
of the plate. All samples were analyzed in duplicate. The plate was incubated overnight 
at 4°C. After a round of washing, 100 μL of detection antibody diluted in Reagent 
Diluent was added to each well of the plate for an incubation period of 1 hr at room 
temperature. The plate was again washed and 100 μL of Avidin-HRP diluted in Reagent 
Diluent was added to each well of the plate. The plate was incubated for 1 hr at room 
temperature. Following a final round of washing, 100 μL of substrate solution 
(Chromogen – tetramethylbenzidine (TMB)) was added to each well of the plate and 
incubated for no more than 15 minutes at room temp. After incubation, 50 μL of stop 
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solution (2N H2SO4) was added to each well of the plate. The optical density was 
determined immediately by a microplate reader at 450 nm. Data was reported as ng/mL 
of cytokine in cell cultured media and plasma or as ng of sAPP-/wet g of brain 
homogenates. Total protein concentration was determined on cell lysates or brain 
homogenates using a BCA Protein Assay Kit. (Thermo Fisher Scientific). 
 
Statistical Analyses 
Western blot band density data was calculated as mean ± SEM for each group of 
mice. Depending on the number of groups in the study, the student’s T-test or the one 
way analysis of variance (ANOVA) was used to determine the significance of differences 
between the means of the groups that were investigated. Statistical analyses of 
neurohistologic/neurochemical markers were also performed using T-test or ANOVA. For 
the social interaction test, two-way ANOVA was used for statistical analysis as there 
were three independent variables involved. If the groups did not meet the required 
assumptions for parametric statistical analyses due to animal mortality or other cause, 
we used the Chi-squared non-parametric test in place of the t-test, Kruskal-Wallis test 
instead of the one-way ANOVA, and Friedman’s two-way ANOVA in place of the two-way 
ANOVA. NCSS/PASS statistical software, Excel and GraphPad were used to assist in 
statistical calculations.  
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CHAPTER 3:  
ELEVATED LEVELS OF sAPP-α IN AUTISTIC PATIENTS  
 
Note to Reader 
Portions of these results have been previously published (Bailey et. al., 2008) 
and are utilized with permission of the publisher. 
 
Introduction 
Amyloid Precursor Protein In Standard Physiological Conditions 
 Although the true function of the amyloid precursor protein remains elusive, the 
crystallized structure of the APP ectodomain (essentially sAPP-α) is compatible with a 
receptor and/or a growth factor role [233]. A lack of APP in cultured hippocampal 
neurons showed that APP increases synaptic function and formation in vitro [234]. 
Combined gene knockout mice for APP and two of its gene family members amyloid 
precursor protein-like protein 1 and 2 (APLP1 and APLP2) show that knocking out both 
APP and APLP2 proved lethal to early postnatal mice, while APP-/-/APLP1-/- mice were 
surprisingly viable [235], suggesting that APP is vital for development but APLP2 can 
compensate for its function. The results of several studies disclosing the features of APP 
knockout mice, which include growth and brain weight deficits, gliosis, defective lipid 
homeostasis, altered circadian locomotor activity and impaired spatial learning [236, 237] 
also hint at APP function. Other studies implicate APP in axonal transport [238, 239] and 
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pro- and anti-apoptotic functions [240]. Through its intracellular domain, produced after 
gamma cleavage, APP appears to be involved in gene regulation, cell motility, neuron 
viability, neuritic outgrowth and synapse formation [240, 182]. In addition to the roles 
described in Chapter 1, the sAPP-α fragment has been shown to either attenuate or 
completely reverse the defects identified in APP knockout mice [237]. 
 A disintegrin and metalloprotease 10 (ADAM 10) and other members of the 
ADAM protein family cleaves APP, in both neuronal and non-neuronal tissues, and other 
proteins such as Notch and TNF-α [241]. ADAM10 cleavage of APP has been associated 
with cholesterol reduction [242]. More pertinently, ADAM10 overexpression significantly 
increases cholinergic, glutamatergic and GABAergic cortical synaptogenesis in vivo, 
confirming the neurotrophic influence of sAPP-α [243]. Administrations of an α-secretase 
inhibitor batimastat to rats caused long-lasting memory impairments in neonates, and 
reversible short-term impairment in adults [244], thus hinting at another role for sAPP-α 
in memory retention. 
 
Autism and the Amyloid Precursor Protein 
Evidence of an association between autism and the amyloid precursor protein 
(APP) was first reported in 2006 by Sokol et al. [171]. According to this report, a 
comparison of different APP fragments in the plasma of autistic and normally developed 
children produced a significant increase in the sAPP-α fragment in the plasma of 
severely autistic patients. There were no differences between patient and control groups 
in the plasma concentrations of full length APP. It was this finding that prompted our 
studies of sAPP-α expression in autistic patient plasma [172]. A later study by the same 
group confirmed the increase in plasma concentration of sAPP-α, and reported 
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corresponding decreases in the amyloid β (Aβ) and sAPP-β fragments, both of which are 
resultant of amyloidogenic APP processing [173]. Both these studies considered autism 
severity, and findings were not identified in patients with mild to moderate autism. A 
recent study on autistics from Saudi Arabia confirms the reduction in levels of the Aβ 
fragments in autistic patients [245]. 
Preliminary results (eventually published) from studies of APP fragments in 
postmortem autistic patient brains demonstrated intra-neuronal “N-terminal truncated 
Aβ” by immunohistochemical staining [246]. However, given that the antibody used to 
identify this fragment also identifies the α-CTF, these studies may actually be 
representing α-CTF, and not a truncated Aβ17-40,42. Due to the unavailability of human 
brain tissue from the hippocampal region, the region of interest was shifted to the 
insular cortex for our studies. The insular cortex is a part of the neocortex that shows 
neurobiological abnormalities in some autistic populations and appears to be involved in 
language and attention [45, 35].  
The following results confirm the presence of the sAPP-α fragment at elevated 
levels in both brain and plasma samples from autism patients. Additionally, the 
increased presence of the α-CTF fragment is shown in the brain.  
 
Results 
Levels of sAPP-α are elevated in the plasma of autistic children 
Blood plasma samples from 25 autistic children and 25 healthy children between 
the ages of 2 and 5 years were obtained from the Autism Genetic Research Exchange 
(AGRE, Los Angeles, California). Fifteen of the samples from each group were from male 
children, with the remaining 10 being from females. Autism diagnoses were determined 
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using the Autism Diagnostic Interview – Revised. These samples were subjected to 
sAPP-α sandwich ELISA developed according to a protocol by Olsson et al. [232]. The 
results of this assay show that the concentration of sAPP-α in plasma samples from  
 
 
 
 
Fig 3.1: Elevated levels of sAPP-α in autism patient plasma. (A & B) Levels of sAPP-α in  
plasma samples from autistic children (n = 25, 15♂, 10♀) and normally developed age-matched 
children (n = 25, 15♂, 10♀) were measured using ELISA. Data are represented as mean±SEM of 
sAPP-α (ng/mg total plasma protein). (C) Increase in plasma levels of sAPP-α in autism patients 
were confirmed using Western blot analysis of sAPP-α protein in plasma samples. Randomly 
selected plasma samples from autistic (n = 15, 11♂/4♀) and healthy age-matched children (n = 
15, 8♂/7♀) were pooled and loaded in triplicate for electrophoresis. (D) Densitometric analyses 
were normalized using total concentration of plasma protein and are represented as mean±SEM 
of Western blot band density.   
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autistic children was significantly greater than the concentrations observed in normally-
developed children (Fig 3.1A). Over 60% of the individual autism patient samples 
contained a greater level of sAPP-α (Fig 3.1B). These ELISA findings were confirmed by 
Western blot analysis, using the monoclonal 6E10 antibody, of 15 randomly-selected 
samples from each group pooled together and loaded in triplicate for gel electrophoresis. 
Selected samples from autistic children contained plasma from 11 males and 4 females, 
while samples selected from normally-developed children contained 8 males and 7 
females. The sample pool of autistic patient plasma expressed significantly increased 
levels of sAPP-α compared to the sample pool from normally-developed child plasma 
(Fig 3.1C) and quantification by densitometric analysis substantiates this observation 
(Fig 3.1D). Band densities were normalized using total concentration of plasma protein. 
 
Levels of sAPP-α and α-CTF are elevated in autistic patient brains 
Frozen insular cortex specimens from the postmortem brain of 6 autism patients 
and 8 normally-developed children were prepared for biochemical analysis and examined 
for levels of sAPP-α using a commercially-available sAPP-α ELISA kit. Table 1 reports the 
demographics and diagnoses of the autism patients and controls from which the 
samples were obtained.  The assay demonstrated that the mean level of sAPP-α in 
autism patient brains was significantly increased compared to the mean level of sAPP-α 
in brains from normally developed children (Fig 3.2a). Two of the individual autism 
patients in particular exhibited a marked increase in brain sAPP-α expression than all the 
other individuals (Fig 3.2b). To test our theory that autism patient brains may be 
expressing the α-CTF resulting from non-amyloidogenic processing, homogenized brain 
sample preparations were subjected to Western blot analysis using the polyclonal  
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Table 1: Human Tissue Sample Demographics 
Patient 
No. #Dx Sex 
Age at 
Death 
(yrs) Cause of Death Ethnicity *PMI 
1 Control F 4.5  Lymphocytic Myocarditis Asian 21 
2 Control M 4.6  Commotio Cordis Caucasian 17 
3 Control M 4.7 Drowning Caucasian 17 
4 Control F 5.9 Drowning Caucasian 20 
5 Control M 8  Cardiac Arrhythmia Caucasian 5 
6 Control M 8.9 
 Hyperthermia and 
Drowning Caucasian 36 
7 Control F 9.6 
 Asphyxia due to 
aspiration to foreign 
material 
African 
American 8 
8 Control M 11.7 Drowning 
African 
American 19 
9 Autism F 4.5 
Multiple Injuries from a 
fall 
African 
American 13 
10 Autism M 5 Asphyxia 
English - 
White 26 
11 Autism M 7.2 Cancer Complications Caucasian 3 
12 Autism M 7.5 Drowning 
African 
American 20 
13 Autism M 9 Seizure Disorder 
English – 
White 27 
14 Autism M 11 
 Acute Hemorrhagic 
Tracheobronchitis Hispanic 27 
 
#diagnosis 
*post mortem interval 
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Fig 3.2: Elevated levels of sAPP-α and α-CTF in autism patient brain. (a & b) Levels of 
sAPP-α in autistic patient brain homogenates (n = 6) and normally developed age-matched 
controls (n = 8) were measured using ELISA. Data represented as mean±SEM. (c & d) Western 
blot analysis shows increased expression of α-CTF in autistic brain homogenates (n = 6) 
compared to healthy, age-matched controls (n = 8). Densitometric data representing the band 
densities of α-CTF normalized with β-actin are represented as mean±SEM.  
 
 
antibody 369, which binds full-length APP and the C-terminal fragments produced by 
secretases. This experiment revealed strikingly greater expression of the α-CTF fragment 
in the autistic patient brain samples compared to brain samples from normally 
developed controls. Expression levels were quantified by band density analysis and 
normalized to β-actin (Fig 3.2c & d).  
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Conclusions 
The experiments detailed in this chapter corroborate the findings of previous 
studies suggesting an association between autism and APP, particularly the sAPP-α 
fragment. Here we discovered a significant elevation in the plasma sAPP-α levels of 2 – 
5 year old autistic children compared to age-matched controls, with over 60% of autistic 
individuals expressing this increase. We also found increased sAPP-α expression in 
insular cortex brain regions of autistic patients compared to age-matched controls. This 
finding was appropriately accompanied by an increase in expression of the α-CTF 
fragment in autism patient brains compared to controls. 
Altogether, these data, garnered from unique sample cohorts, demonstrate that 
sAPP-α is expressed at elevated levels in both the brain and plasma of patients 
diagnosed with autism. Additionally, the non-amyloidogenic processing pathway for APP 
is more strongly implicated, particularly in the autistic patient brain.  
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CHAPTER 4:  
BEHAVIORAL CHARACTERIZATION OF hsAPP-α TRANSGENIC MICE 
 
Introduction 
Cognitive and Behavioral Comorbidities of Autism 
Mental retardation, or intellectual disability, is a common comorbidity of autism 
found in up to 80% of autism patients [247, 36, 248]. According to one review, autistic 
individuals suffer from a single common cognitive deficit that presents as an inability to 
understand intentions and beliefs [249]. Without intellectual disabilities, autistic patients 
can function at an average to superior range of cognition, but special interventions for 
social skills have been developed for autism patients with this comorbidity [250]. Anxiety 
disorders are also highly prevalent in populations of children and adolescents with 
autism, implying that anxiety is an additionally substantial comorbidity [251]. Estimates 
of anxiety as a comorbidity of autism range from 11 – 84% [252]. Moreover, autistic 
children may exhibit either hyperactivity or hypoactivity [253]. One study suggests that 
hyperactivity is typically seen during the pre-school period of the life of a child with 
autism, while hypoactivity is demonstrated during the adolescent years[253]. Other 
studies report that hypoactivity was exhibited by infants under 4 years of age who were 
later diagnosed with autism [254, 255]. Behavior tests observing these co-morbidities in 
mice were performed on our mouse model. Other comorbidities of autism include 
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epilepsy [256, 90], sleep disorders [257], aggression [258], and other clinical disorders 
[253].  
 
“Autistic Mouse Models”: Design and Evaluation 
Given the heterogeneous phenotype and unknown etiology of autism spectrum 
disorder, animal models generated to address questions pertaining to the disorder are 
designed based on single potential causative or participating agents. These agents range 
from susceptibility genes, such as the CNTNP2 [259], CNTN4 [25], RELN [21], NLGN 3 
and 4 [26], to lesions of specific brain regions like the amygdala or cerebellum, to 
hormones like oxytocin, vasopressin and serotonin, [260] and environmental triggers 
such as maternal immune activation [157, 261]. Animals which have been used for 
studies on autism include several species of rodent as well as primates [262, 32, 77, 
139], however mice are most commonly used. In principle, it is inaccurate to label any 
animal model as an “autism model” due to the unknown etiology and heterogenous 
phenotype of the disorder. It is also worth noting that many accepted models of 
neurological/psychiatric disorders do not reconstitute all the features of the disorders 
they aim to imitate.  
Mouse models of autism are evaluated using behavior tests designed to measure 
features of the three core behavioral characteristics that are used to diagnose the 
disorder: social interaction, communication and repetitive behavior, as well as behaviors 
that mirror co-morbid features of the disorder [263, 264, 169]. These behavioral traits in 
mice with face validity to the main autistic behaviors in patients are indispensible 
because other neurobiological attributes of the disorder are heterogeneous and no 
definitive biomarkers have been identified. Of the three core features, impairment in 
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social interaction is most prominently studied, with reductions being identified by 
different testing methods [168]. Crawley et al. designed a now widely-accepted social 
approach task that measures the tendency in mice to either socialize with an unfamiliar 
mouse or to explore a novel object [265, 157]. In several studies, reduced levels of 
sociability identified by this test suggest autistic-like behavior [266, 170].  
In this chapter we present data relating the successful generation of a mouse 
model (TgsAPP-α mice) that recapitulates the sAPP-α-related features identified in 
autistic patients. We also demonstrate the behavioral attributes observed in TgsAPP-α 
mice and a change in a synaptic marker that may explain them. 
 
Results 
Elevated levels of hsAPP-α in individual brain regions of TgsAPP-α mice  
The transgenic murine model of sAPP-α overexpression we generated (TgsAPP-α 
mice) to mimic the condition seen in autism patients (described in chapter 3) was 
characterized using biochemical and behavioral techniques. The DNA sequence coding 
for human sAPP-α was inserted with a murine prion protein promoter to drive its 
expression predominantly in the brain. Brain region homogenates from the cortex and 
hippocampus of 3 month old TgsAPP-α littermates were examined for protein expression 
of hsAPP-α using Western blot analysis with monoclonal 6E10 antibody. As expected, 
TgsAPP-α+/+ and TgsAPP-α+/- mice express hsAPP-α in a genotype-dependent manner, 
while in wild-type littermates hsAPP-α is not present (Fig 4.1a & c).  
Additionally, hsAPP-α levels in homogenates from each of the two brain regions 
were measured using a commercially-available ELISA kit. Assay results clearly show a 
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genotype-dependent increase in hsAPP-α levels in cortex and hippocampus regions, and 
the absence of hsAPP-α in wild-type littermates (Fig 4.1b & d). 
 
 
Fig 4.1: Expression of hsAPP-α in cortex and hippocampus regions of TgsAPP-α 
mouse brain. Immunoblots showing increased sAPP-α in the cortex (a) and hippocampus (c) 
brain regions of 3 month old TgsAPP-α+/+ (n = 3) and TgsAPP-α +/- (n = 3) compared to wild-
type (n = 2) littermates from a single family. Increases in hsAPP-α in cortex (b) and hippocampus 
(d) regions of these TgsAPP-α mice compared to littermate controls were also demonstrated by 
ELISA. ELISA data is represented as mean ± SD of ng of sAPP-α/mg of total protein. ***p < 
0.001. 
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Elevated levels of hsAPP-α in whole brain and plasma from TgsAPP-α mice  
The commercially-available ELISA kit was also used to measure hsAPP-α levels in 
whole brain homogenates and plasma from TgsAPP-α mice. In these experiments, 
TgsAPP-α mice were 6 week old littermates. ELISA results from the whole brain 
homogenates complement the findings observed in cortex and hippocampus regions, 
showing genotype-dependent increases in the levels of hsAPP-α in TgsAPP-α mice 
compared to wild-type littermates (Fig 4.2A). Moreover, TgsAPP-α mouse plasma 
contain hsAPP-α and the levels increase significantly in a genotype-dependent manner, 
with wild-types showing no evidence of hsAPP-α expression (Fig 4.2B).  
 
 
 
 
Fig 4.2: Whole brain homogenate and plasma concentrations of hsAPP-α in TgsAPP-α 
mice. Concentrations of hsAPP-α in homogenates (ng/mg protein; A) and plasma (ng/ml plasma; 
B) from 6-wk-old TgsAPP-α+/+ (n = 3), TgsAPP-α+/- (n = 3) and wild-type mice (n = 4) 
littermates (all from one family) were measured by ELISA. Results are represented as means ± 
SE. ***p = 0.001. 
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Sequence of behavioral experiments and mouse groups 
 Animal exposure to the activities and stimuli involved with various behavioral 
tasks may impact the behavior of the same animals during other tasks with which it is 
made to perform. Therefore, it is worth noting that the rotarod, fear conditioning, open 
field and social interaction tasks were performed on the same groups of mice, and in 
that order. Animals were allowed an inter-experimental period of no less than 6 days 
during which no behavioral tests were administered and animals were housed and 
maintained as mentioned in Chapter 2. The elevated plus maze and the Morris water 
maze behavior tests were each performed on distinct groups of mice.  
  
TgsAPP-α mice show hypoactivity but no change in anxiety 
In order to assess baseline locomotor activity and anxiety in 3 month old 
TgsAPP-α mice and wild-type littermate controls, we used the open field behavior test to 
measure total distance traveled, and time spent in the center of the 17” x 17” square 
apparatus. Transgenic mice were not separated by homozygous or heterozygous 
genotype for this test. There was no significant difference between TgsAPP-α mice and 
WT controls in time spent in the center of the apparatus (Fig 4.3A). However, TgsAPP-α 
mice traveled significantly less distance around the apparatus compared to WT 
littermates (Fig 4.3B). These results imply that while there is no significant difference in 
anxiety levels between transgenic mice and WT littermate controls, transgenic mice are 
hypoactive compared to WT mice, based on the decrease, relative to controls, observed 
in locomotor activity.  
The absence of significant anxiety changes in TgsAPP-α mice, compared to WT 
littermate controls, was further substantiated by the performance of these mice on the 
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elevated plus maze task. For this task, 3 month old animals were monitored for 5 mins 
using tracking software and measurements of time spent in the open arms and numbers 
of entries into the open arms were recorded. For both these factors, results of behavior 
analysis showed that there was no significant difference between transgenic mice and 
their wild-type littermates (Fig 4.4A & B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Hypoactivity in hsAPP-α transgenic mice in the open field task. Wild-type (n 
= 12) and transgenic (n = 13) mice were placed in an open field apparatus for 5 minutes. 
Activity was recorded on video and later scored using Ethovision software. (A) There was no 
significant difference between wild-type and transgenic mice in time spent in the center of the 
open field, suggesting no difference in anxiety levels. (B) Transgenic mice traveled significantly 
less total distance in the open field compared to wild-type mice, which suggests hypoactivity. 
Data is represented as mean ± SEM, and *p < 0.05. 
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To investigate whether the decrease in locomotor activity in TgsAPP-α mice was 
due to impaired motor coordination and balance, mice were subjected to the rotarod 
task. In this task, 3 month old mice underwent 8 trial runs on an accelerating rotating 
rod over a 48 hour period, with 5 minute inter-trial intervals. The length of time that 
each mouse remained on the rod was recorded. The results of this task revealed no 
significant differences between TgsAPP-α mice and WT littermates in motor coordination 
and balance on the rotarod (Fig 4.5). Altogether, these data suggest that TgsAPP-α mice 
do not exhibit anxiety but show hypoactivity that is not due to impairments in motor 
coordination and balance.  
 
 
 
 
Figure 4.4: No anxiety observed in hsAPP-α transgenic mice in elevated plus maze 
task. Transgenic (n = 10) and wild-type mice (n = 7) mice were placed in maze for 5 min. Data 
recorded using Any Maze software. (A) There was no significant difference in time spent in open 
arms of maze between wild-type and transgenic mice. (B) There was no significant difference in 
number of entries into open arms between wild-type and transgenic mice, suggesting no 
difference in activity during this task. Data is represented as mean ± SEM. 
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Figure 4.5: Motor coordination and balance in hsAPP-α transgenic mice. Wild-type (n = 
12) and transgenic (n = 13) mice were subjected to eight 5 min trials on the rotarod over a 48 h 
period. There was no significant difference between wild-type and transgenic mice in latency to 
fall off the rotarod. Data is represented as mean ± SEM. 
 
 
 
No cognitive impairment in adult TgsAPP-α mice 
 
Cognition in TgsAPP-α mice and wild-type controls was evaluated by two 
methods. First, 3 month old TgsAPP-α mice and wild-type littermates were subjected to 
associative learning by fear-conditioning followed 24 hours later by amygdala-dependent 
contextual and hippocampal-dependent cued acquisition assessments. For this 
experiment, heterozygous and homozygous TgsAPP-α mice were not delineated. Both 
groups of mice showed equivalent rates of learning of the stimulus pairings, as 
evidenced by the increase in percentage freezing time with progression of the 7-min 
training session (Fig 4.6A). Additionally, there were no significant differences between 
the groups in contextual or cued assessments, based on a comparison of the percentage 
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of the total test time spent freezing (Fig 4.B & C), supporting the implication that both 
groups learned similarly.  
 
 
 
 
Figure 4.6: No impairment in fear-conditioned associative learning and memory in 
hsAPP-α transgenic mice. Wild-type (n = 12) and transgenic (n = 13) mice were trained in a 
fear-conditioning chamber, then tested for contextual and cued memory 24 hours later. (A) 
Transgenic mice exhibited the same rate of learning as wild-type mice. (B) For the amygdala-
dependent contextual memory test, there was no significant difference between wild-types and 
transgenics in percentage freezing. (C) For the hippocampus-dependent cued memory test, there 
was no significant difference between genotype groups. Data is represented as mean ± SEM. 
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Secondly, the Morris water maze test, which evaluates spatial learning and 
memory, was performed on TgsAPP-α mice and WT littermates. Mice were trained to 
find a hidden platform inside a pool filled with opaque water using only spatial cues by 
undergoing four 1-min trials per day for 7 days. Training was followed by a single 1-min 
probe trial in which the hidden platform was removed. Latency times to find the 
platform for trials during training, as well as the time spent by each mouse in the target 
quadrant of the pool were recorded. Heterozygous and homozygous TgsAPP-α mice 
were categorized and compared with WT littermates for this test. All three genotypes of 
mice showed similarly successful spatial learning, as implied by the decrease in latency 
time to find the platform over the week-long training period (Fig 4.7A). In addition, all 
three genotype groups spent more time in the target quadrant of the pool compared to 
the other three quadrants, and there was no significant difference between the groups 
in time spent inside the target quadrant (Fig 4.7B). There was also no significant 
difference between the groups in the number of platform crossings (data not shown). 
This further implies that all the mouse groups remembered the position of the platform 
based on spatial cues. 
Taken together, this data demonstrates that there is no impairment in the 
cognitive abilities of TgsAPP-α mice, and sAPP-α therefore has no effect on cognition.  
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Figure 4.7: No deficits in spatial cognition of hsAPP-α transgenic mice. Wild-type (n = 
11), heterozygous (n = 13), and homozygous (n = 10) hsAPP-α mice were subjected to 7 days of 
training in the Morris water maze task, followed by a probe trial on Day 8. (A) The decline in the 
slopes of the lines for each genotype suggests that all three groups learned the location of the 
hidden platform in the water maze. (B) There was no significant difference in the number of 
target platform crossings between the three genotypes. Data is represented as mean ± SEM. 
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Male TgsAPP-α show lack of preference for sociability 
For social interaction observations, TgsAPP-α and WT littermate test mice were 
observed for 10 minutes in a 3-chambered apparatus containing an empty wire cage on 
one end and a wire cage containing a stranger mouse on the other end. Measurements 
were recorded after a 10-min habituation period during which no stranger mouse was 
present inside the apparatus. Homozygous and heterozygous mice were evaluated as 
one group of mice for this study. Based on total distance traveled during the habituation 
phase of this task, there was no evidence of hypoactivity in TgsAPP-α mice in this test 
(Fig 4.8A) and both groups of mice demonstrated increased preference for social 
interaction with a stranger mouse (Fig 4.8B). However, when each of the groups were 
separated by sex, we noticed that there was no significant difference in the periods of 
time that male TgsAPP-α mice (n = 4) spent in each of the two side chambers, while 
wild-type mice (n = 5) spent significantly more time in the chamber containing the 
stranger mouse than in the chamber with the empty wire cage (Fig 4.8C). On the 
contrary, TgsAPP-α and WT female mice in this study both showed increased preference 
for social interaction (Fig 4.8D). This finding demonstrates a decreased preference for 
sociability in male TgsAPP-α mice compared to both male WT controls and female mice, 
irrespective of genotype.  
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Figure 4.8: Male transgenic mice exhibit deficient social interaction with a stranger 
mouse compared to wild-type male mice. (A) During habituation phase of task, all mice 
traveled similar distances. (B) Without separation by sex, transgenic mice show preference for 
interaction with a strange mouse. (C) Male transgenic mice show no preference for social 
interaction. (D) Female transgenic mice show preference for social interaction. Data is 
represented as mean ± SEM and **p < 0.01, ***p < 0.001.  
 
 
Increased synaptophysin expression in TgsAPP-α mice 
 In attempt to explain the behavioral changes we observed in the TgsAPP-α mice, 
and given that the sAPP-α fragment is a proven neurotrophic factor, we measured levels 
of synaptophysin in transgenic mice and wild-type littermates at different ages using 
Western blot analysis (Fig 4.9). Synaptophysin  is  a  38kDa  vesicle-bound  glycoprotein 
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Figure 4.9: Synaptophysin expression in brain homogenates from transgenic mice 
and wild-type littermate controls. Transgenic mice express increased levels of synaptophysin 
in whole brain homogenates compared to their wild-type littermates. (a) Whole brain 
homogenates from 9 day old, 3 month and 4 month old transgenic mice were probed for 
synaptophysin expression using Western blot. Actin expression was also observed as control. (B) 
Densitometric analysis of synaptophysin Western blot. Data is represented as mean ± 5% 
confidence interval.  
 
 
found within synapses that is used as a measure of synapse numbers or synaptic density 
[267]. Whole brain homogenates from 9 day old, 3 month old, and 4 month old TgsAPP-
α mice and wild-type littermates were probed with polyclonal synaptophysin antibody. 
The specific genotypes of the transgenic animals were not identified for these 
experiments.  Our results showed that TgsAPP-α mice express greater levels of 
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synaptophysin in whole brain than their WT littermates (Fig 4.9a & b). There was 
increased expression in 9 day old mice compared to 3 and 4 month old mice, 
irrespective of genotype, and there was also a reduction in the differences in 
synaptophysin expression between WT and TgsAPP-α mice as the age of the animals 
increased. Overall, this data suggests that over-expression of sAPP-α leads to an 
increase in synaptophysin expression, particularly at the early postnatal stage of brain 
development. 
 
Conclusions 
Our purpose for designing the TgsAPP-α mouse is to determine the role of sAPP-
α over-expression in the pathophysiology of autism. Our results verify that we have 
successfully generated a transgenic mouse that models the biochemical elevations of 
hsAPP-α concentration observed in autism patient brain and plasma. TgsAPP-α mice 
overexpress hsAPP-α in their entire brain, and particularly in the cortex and 
hippocampus regions, and we serendipitously discovered that TgsAPP-α mice 
overexpress hsAPP-α in their plasma as well, thereby mimicking the condition we 
confirmed in different sets of autism patients.  
Additionally, our data lead to the conclusion that TgsAPP-α mice exhibit 
hypoactivity and decreased preference for social interaction. Hypoactivity was not due to 
impaired motor coordination or imbalance, and the mice did not demonstrate variations 
in anxiety or alterations in associative or spatial cognitive ability. Social interaction 
deficits were limited to male TgsAPP-α mice. These behavioral findings imply that sAPP-
α overexpression may specifically affect the frontal and motor cortex brain regions of the 
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mice, but not the hippocampus or amygdala regions, all of which have been implicated 
in autism neuropathology.  
Finally, we conclude that sAPP-α over-expression leads to increased whole brain 
levels of synaptophysin during early postnatal brain development, which may contribute 
to an explanation for the altered behavior observed in autistic patients.  
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CHAPTER 5:  
IMMUNOLOGICAL EFFECTS OF hsAPP-α OVER-EXPRESSION  
 
Note to Reader 
Portions of these results have been previously published (Bailey et. al., 2012) 
and are utilized with permission of the publisher. 
 
Introduction 
T-lymphocyte Differentiation and Maturation 
 All circulating T-lymphocytes in mammalian systems are generated in the thymus, 
which is the center of T-cell differentiation and maturation in the body [268]. These 
processes begin with the migration of hematopoietic progenitor cells from the bone 
marrow. The cells proliferate and go through a series of differentiation steps that are 
identified by the expression of cluster of differentiation (CD) proteins on the cell surface. 
Progenitor cells lack CD4 and CD8 during the first four stages of differentiation, which 
are therefore known as the double negative (DN) stages. As they advance from DN 1 to 
DN 4, immature T-lymphocytes express varied combinations of CD44 and CD25 surface 
proteins. The cells then become CD4+/CD8+ double positive (DP) cells and then finally 
mature into single positive (SP) CD4+ or CD8+ T-lymphocytes [269].  
Low expression levels of APP in thymic stromal cells may contribute to T-cell 
maturation by affecting communication between thymocytes and thymic stromal cells 
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[270]. However, APP is not expressed in developing thymocytes and is not required for 
T-cell maturation, as shown by the successful development of T-cells in the thymus of 
APP knockout mice [224]. 
 
Apoptosis in T-cell Maturation 
 Apoptosis is a key factor in the T-cell development process and occurs at three 
key points of T-cell maturation: β-selection, positive selection and negative selection 
[271]. At the DN3 stage, cells undergo β-T-cell receptor (β-TCR) rearrangement; 
thymocytes on which the TCR does not reassemble correctly do not function properly. 
They therefore fail to survive the DN3 stage and undergo apoptosis [272]. Later in the 
process, during positive selection, non-functional double positive thymocytes die 
apoptotically due to neglect [273], while cells with TCRs that are highly reactive to self-
antigens are eliminated by apoptosis during negative selection[274]. The vast majority 
(97%) of immature DP T-cells die during positive selection [275]. Cytoplasmic domain 
fragments of APP have been shown to induce apoptosis in T-cell lines [276].  
 
Apoptotic Signaling Proteins 
 Caspases and the Bcl-2 family of proteins regulate activation of the apoptotic 
process. The Bcl-2 family proteins are apoptotic regulators, while caspases make up the 
machinery responsible for carrying out the programmed cell death [277, 278]. Caspase 
3 is an effector caspase that is activated by way of cleavage by initiator caspase 9 [279]. 
Bcl-2 and Bax are competing apoptosis regulators with opposing functions; Bcl-2 
reduces apoptosis [280, 281] and Bax promotes the process [282, 283]. One study 
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suggests that the competing ratio of Bcl-2 to Bax determines the survival or death result 
of an apoptotic stimulus [282].  
 While the PI3K/Akt and Notch signaling pathways are involved in other separate 
cell processes (PI3K/Akt signaling is instrumental in proliferation while Notch is crucial 
for cell differentiation and homeostasis), both pathways contribute to signaling apoptosis. 
In particular, Notch3 promotes expression of anti-apoptotic Bcl-2 and reduces 
expression of pro-apoptotic Bax [284]. These actions by Notch are not carried out by 
direct association of Notch with the Bcl-2 family proteins but, as evidence suggests, via 
other pathways, including the PI3K/Akt pathway [285, 286]. Notch-induced T-cell 
development requires PDK1, a key player in the PI3K pathway [287]. Studies suggest 
that activated Notch can cause Fas-induced apoptosis in mature T-cells through 
phospho-Akt [288]. Notch1 in particular plays an essential and specific role in T-cell 
development [289]. This conclusion is appropriately based on the fact that irradiated 
wild-type mice reconstituted with Notch1-deficient bone marrow displayed several 
thymus/thymocyte abnormalities, including reduced size, cell number and architecture 
and significant decreases in DP and SP thymocytes [290]. Overexpression of NICD1 
(Notch1 intracellular domain) in a thymoma cell line increased expression of Bcl-2 and 
thymocytes from NICD-overexpressing mice express resistance to glucocorticoid-induced 
apoptosis [274], so high levels of Notch1 and NICD1 lead to reduced apoptosis. 
Interestingly, NICD-overexpressing mice also contained higher numbers of CD8+ SP cells 
[291]. 
 The PI3K/Akt pathway is required for survival and proliferation during thymocyte 
development, particularly at the β-selection check point [292]. Mice that lack PI3K 
signals have defective thymocyte survival [293] and constitutive activation of Akt 
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increases thymocyte survival [294]. PI3K activates Akt by phosphorylation; and Akt 
functions in an anti-apoptotic manner, inhibiting the activity of pro-apoptotic Bcl-2 family 
proteins and initiator caspase 9 by phosphorylation [295, 296].  
 
ZAP-70 and T-cell Activation 
The δ-chain-associated protein kinase 70 (ZAP-70) is a cytoplasmic Src family 
protein tyrosine kinase that is mainly expressed in T-cells and is crucial for their 
development and function [297]. The absence of ZAP-70 in patients leads to severe 
combined immunodeficiency (SCID) in patients due to a lack of functional T-cells in 
peripheral blood [298, 299]. In particular, ZAP-70 is critically involved in the initiation of 
intracellular T-cell signaling resulting from T-cell receptor (TCR) engagement [300, 301]. 
After recruitment to immunoreceptor tyrosine activation motifs (ITAMs) within the CD3 
and δ subunits of the TCR complex, cytosolic ZAP-70 becomes activated by 
phosphorylation and subsequently phosphorylates adaptor proteins which go on to 
recruit other signaling molecules, thereby initiating biochemical events downstream in 
signaling cascades that ultimately lead to activated T-cell responses such as 
differentiation, proliferation and cytokine secretion [302, 303].  
Chapter 5 describes the changes in populations and function of immunological 
players in TgsAPP-α mice compared to WT littermate controls. The focus, here, is on the 
effects of sAPP-α overexpression on T-cell development and function. 
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Results 
Increased IFN-γ, IL-2 and IL-4 secretion from TgsAPP-α splenocytes after 
immune challenge 
Evidence supports the theory that sAPP-α plays a role in immune cell activation. 
In order to investigate how elevated levels of sAPP-α could be affecting immune cell 
function, we stimulated splenocytes from TgsAPP-α mice and WT littermates in vitro and 
measured the levels of cytokines produced using ELISA. Splenocytes were challenged 
with ConA, a well-known T-cell mitogen [304], and we quantified the secretion of 6 
different cytokines using respective commercially-available ELISA kits. Our results 
showed that splenocytes from TgsAPP-α mice produced markedly higher levels of IFN-γ, 
IL-2, and IL-4 after challenge compared to WT littermates (Fig. 5.1, top panel), 
suggesting that the T-cell immune response is enhanced as a result of hsAPP-α 
overexpression. Furthermore, significant differences between TgsAPP-α+/- and TgsAPP-
α+/+ mice in levels of IFN-γ and IL-4 secretion reveal a genotype-dependent effect of 
hsAPP-α on the stimulation of T-cells (Fig. 5.1, top panel). We also measured the 
release of TNF-α, IL-1β, and IL-6 from mouse splenocytes after ConA challenge; 
however, we did not observe differences between TgsAPP-α mice and WT littermates in 
the levels of each of these cytokines (Fig. 5.1, bottom panel). This data suggests that 
elevated levels of hsAPP-α contributes to altered pro-inflammatory cytokine secretion 
from T-cells in transgenic mice compared to WT littermates. 
 
Altered B- and T-cell populations in TgsAPP-α mice 
In attempt to explain the cause of increased cytokine production in TgsAPP-α 
mice, we sought to establish the relative population sizes of immune cells represented in 
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the spleen. Splenocytes from TgsAPP-α mice and WT littermates were isolated and B- 
and T-cell populations assessed using flow cytometry. We used antibodies against CD19 
and CD3 to identify B and T cells respectively. Analysis revealed a significant decrease in 
the percentage of CD19+ cells from TgsAPP-α+/+ mouse splenocytes compared to those 
from WT littermates (Fig. 5.2A, & C, top panel). In contrast, TgsAPP-α+/+ mouse 
splenocytes comprise a markedly increased percentage of CD3+ cells compared to 
splenocytes from WT littermates (Fig. 5.2A & C, top panel).  
 
Figure 5.1: T-cell derived cytokines are significantly increased in TgsAPP-α mice 
splenocytes after T-cell mitogen challenge. Splenocytes were isolated from 6 week-old 
transgenic mice and wild-type littermates, cultured in 24-well plates at 5 x 106 cells per well, and 
treated with 5 ug/mL of ConA for 18 h. Cell supernatants were collected and subjected to ELISA 
for the cytokines shown above. Intracellular protein concentrations were measured in cell lysates.  
Results are displayed as mean ± standard error in ng or pg per mg of intracellular protein. **P < 
0.01, ***P < 0.001. 
 
 
CD3+ T-cells were further classified with antibodies against CD4 and CD8, which 
revealed opposing alterations in CD4+ and CD8+ cell populations from TgsAPP-α mouse 
splenocytes compared to WT littermate splenocytes. TgsAPP-α+/+ mice possess a 
61 
 
significantly lower percentage of CD3+/CD4+ cells in the splenocyte population compared 
to WT littermates (Fig. 5.2B & C, bottom panel). Conversely, the percentage population 
of CD3+/CD8+ cells is considerably greater in TgsAPP-α+/+ mouse splenocytes than in WT 
controls (Fig. 5.2B & C, bottom panel). In addition to demonstrating the presence of 
modifications to the immune cell populations in splenocytes from TgsAPP-α mice, these 
data imply that an increase in the population of CD3+/CD8+ cells may explain the 
increased cytokine production observed after splenocyte challenge (Fig. 5.1). 
 
 
 
Figure 5.2: B- and T-cell populations are altered in TgsAPP-α mice. Splenocytes were 
isolated from transgenic mice and wild-type controls, labeled with cell-specific antibodies and 
analyzed using flow cytometry. (A) CD19+ B-cells and CD3+ T-cells from splenocytes were 
identified by flow cytometry. (B) CD3+ T-cells from splenocytes were labeled with CD4 and CD8 
and analyzed by flow cytometry. (C, top panel) B- and T-cell populations are quantified by 
percentage of total splenocyte population. (C, bottom panel) T-cell populations are quantified by 
percentage of total CD3+ cell population. **P  < 0.01. 
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T-cell populations are altered in TgsAPP-α mouse thymus 
T-cell populations in the thymus, the site of T-cell development [305, 268] were 
examined in TgsAPP-α mice and wild-type littermate controls. Thymocytes from were 
isolated and analyzed with flow cytometry. The populations of thymocytes present at the 
different stages of development in the thymus were classified using a hierarchical 
detection strategy based on antibody co-labeling of the unique cell-surface marker 
combinations expressed by each type of cell. Initially, mature and immature thymocyte 
populations were identified using CD4 and CD8 antibodies. Immature thymocytes at 
each of the 4 stages were then characterized using antibodies against CD44 and CD25. 
Flow cytometry analysis revealed marked disparities in mature and immature T-cell 
populations in the thymus of TgsAPP-α+/+ mice compared to WT littermates (Fig 5.3A & 
C, top panel). TgsAPP-α+/+ mouse thymocyte populations contained significantly less 
CD4+/CD8+ double-positive (DP) T-cells than WT thymocyte populations. Further, 
thymocytes from TgsAPP-α+/+ mice comprised a greater percentage of the individual 
CD4+ and CD8+ cell populations compared to WT littermate thymocytes (Fig. 5.3A & C, 
top panel). Understandably, the CD4-/CD8- double-negative (DN) population in TgsAPP-
α+/+ mouse thymocytes was considerably increased compared to the same population in 
WT littermate thymocytes (Fig. 5.3C, top panel).  
We honed in on the DN population of mouse thymocytes in all 3 groups of mice 
and found significant alterations in the population percentages of 3 of the 4 immature 
thymocyte classifications (Fig 5.3C bottom panel). In comparison to thymocytes from 
WT littermates, there were decreases in the percentages of the CD25+/CD44+ and the 
CD25-/CD44- populations of thymocytes in TgsAPP-α+/+ mice.  On the contrary, the  
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Figure 5.3: T-cell and thymocyte populations are altered in TgsAPP-α mice. (A, B) 
Thymocytes prepared from transgenic mice and wild-type littermates were labeled for CD4, CD8 
(A), CD25 and CD44 (B) cell surface markers and analyzed by flow cytometry to identify double 
positive and double negative T-cells. (C) Quantification of CD4/CD8 double positive, single 
positive and double negative populations in gross thymocyte preparations (top panel) and of 
CD44/CD25 double positive, single positive and double negative cells within the CD4/CD8 double 
negative population (bottom panel). *P < 0.05, **P < 0.01. 
 
 
percentage CD44+/CD25- population was greater in TgsAPP-α+/+ mouse thymocytes than 
in WT littermate thymocytes (Fig 5.3C bottom panel). Even though the percentages of 
the individual populations of thymocytes at the 4 stages of development (as identified by 
CD4- and CD8- markers) were different between the groups, the overall representative 
population pattern was the same for all 3 groups (Fig. 4C, top panel). However, 
particularly for the DN population, TgsAPP-α mice demonstrated a unique representation 
pattern in which the CD44+/CD25- population appeared larger than the CD44-/CD25+ 
population. In the WT littermate group, these two populations were statistically similar 
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in percentage population (Fig. 4C, bottom panel). Collectively, our findings imply that T-
cell development may be altered by the high levels of sAPP-α characteristically produced 
in TgsAPP-α mice.  
 
Apoptosis reduced in TgsAPP-α mice 
Given our data showing that developing T-cell populations in the thymus are 
altered in TgsAPP-α mice, as well as the fact that apoptosis is involved in T-cell 
development, we explored whether apoptosis or the expression of apoptotic signaling 
proteins was affected in these mice. Thymus tissue from TgsAPP-α mice and WT 
littermates was stained with an antibody against cleaved caspase-3, and cells 
undergoing apoptosis were identified by TUNEL assay. Caspase-3, an effector protein in 
the apoptotic process, is widely used as a marker of apoptosis [306]. We also studied 
the expression of key proteins involved in apoptotic signaling via Western blot analysis. 
Both immunohistochemistry and biochemical analyses demonstrated that TgsAPP-α+/+ 
mice displayed a significant decrease in cleaved caspase-3 expression in the thymus 
compared to both TgsAPP-α+/- mice and WT littermates (Fig. 5.4A & C and Fig. 5.5A), 
suggesting decreased apoptosis. This finding was substantiated by the TUNEL assay, 
which detected fewer positively labeled thymus cells in TgsAPP-α+/+ mice compared to 
TgsAPP-α+/- mice and WT littermates (Fig 5.4B & D). 
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Figure 5.4: Apoptosis is reduced in TgsAPP-α mice thymi. (A, B) Thymus tissue from 6 
week old transgenic mice and wild-type littermates (n=3 per group) fixed and stained with an 
antibody against cleaved (active) caspase 3 (A) and with TUNEL (B, red) and DAPI (B, blue). (C, 
D) Quantification of active caspase 3 (C) and TUNEL (D) staining by image analysis using 
percentage of area stained. *P < 0.05, **P < 0.01. 
 
 
Western blot analyses of thymus tissue showed increased expression of anti-
apoptotic protein Bcl-2 and reduced expression of pro-apoptotic protein Bax in TgsAPP-
α+/+ mice, compared to TgsAPP-α+/- mice and WT littermates (Fig. 5.5A). Moreover, 
decreased levels of active caspase-3 were found in TgsAPP-α mice compared to WT 
littermates (Fig. 5.5A). Protein levels of Notch1, Notch intracellular domain (NICD), 
phosphorylated phosphoinositide 3-kinase (phospho-PI3K), and Akt were investigated 
using Western blot analyses as well. Our data showed a genotype-dependent increase in 
Notch1 and NICD expression in TgsAPP-α mice and WT littermates (Fig. 5.5B). We also 
noted increases in the expression of phospho-PI3K and phospho-Akt; however, these 
increases appeared unaffected by genotype and the differences in expression of these 
proteins among the three groups of mice were not significant (Fig. 5.5B). Together, our 
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findings indicate that TgsAPP-α+/+ mice exhibit a marked reduction of the occurrence of 
the apoptotic process. 
 
Impaired recall response in splenocytes from TgsAPP-α mice 
Mammalian T-cells possess a unique memory capability that allows them to 
remember antigens from initial challenges to the immune system for rapid mobilization 
towards more potent defensive action by the adaptive immune system. We investigated 
this recall response function in splenocytes isolated from TgsAPP-α+/+ mice and WT 
littermates immunized with myelin oligodendrocyte protein (MOG) to test the effect of 
sAPP-α on immune cell function. Isolated splenocytes from MOG-immunized mice were 
treated with ConA or MOG in vitro, and pro-inflammatory cytokine release was measured 
by ELISA. After treatment with ConA, splenocytes from MOG-immunized TgsAPP-α+/+ 
mice released significantly higher levels of IFN-γ, IL-2, and IL-4 compared to WT 
littermates (Fig. 5.6A). ConA challenge produced a strange decrease in secreted IL-6 
from TgsAPP-α+/+ mice compared to WT littermates. Nevertheless, as seen in the 
previous experiment involving cytokine release after immune challenge (Fig. 5.1), no 
significant differences were found between transgenic and WT littermates in the release 
of IL-1β and TNF-α (Fig. 5.6A). Interestingly, splenocytes from MOG-immunized TgsAPP-
α+/+ mice that were treated in vitro with MOG secreted significantly lower levels of IFN-γ, 
IL-2, and IL-4 compared to WT littermate splenocytes (Fig. 5.6B). Reduced IL-6   
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Figure 5.5: Expression profile of apoptotic signaling molecules confirm reduced 
apoptosis in sAPP-α mouse thymocytes. Thymus homogenates from 6 week old transgenic 
mice and wild-type littermates were probed for protein expression using Western blot. (A) 
Antibodies against human APP (6E10), apoptotic proteins Bcl-2, Bax, caspase 3 and cleaved 
caspase 3, and β-actin were used. Bottom panel shows the ratio of cleaved to total caspase 3 
expression after densitometric analysis. (B) Antibodies against Notch, NICD, phosphorylated and 
total PI3K, phosphorylated and total AKT, and actin were used. Bottom panel shows the ratio of 
NICD to Notch1 after densitometric analysis. *P < 0.05, ***P < 0.001.  
 
 
secretion observed in TgsAPP-α+/+ mice after MOG treatment was not statistically 
significant, and levels of IL-1β and TNF-α were not significantly different from WT 
littermates (Fig. 5.6B). We therefore deduce that the recall response in T-cells from 
TgsAPP-α mice may be impaired.  
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We went on to examine the expression of phosphorylated δ-chain-associated 
protein kinase 70 (ZAP70) in splenocyte lysates of MOG-immunized TgsAPP-α mice and 
WT littermates by Western blot analysis so as to understand why the T-cell memory 
response is abated. ZAP70 is expressed in T-cells and is involved in the initiation of T-
cell signaling [297]. Our findings demonstrate that splenocyte lysates from TgsAPP-α+/+ 
mice expressed less phosphorylated ZAP70 (phospho-ZAP70) compared to WT 
littermates, irrespective of immunization with adjuvant only (CFA/PTX) or with MOG and 
adjuvant (Fig. 5.6C). Densitometry showed that the ratio of phospho-ZAP70 to total 
ZAP70 is significantly reduced in TgsAPP-α+/+ mice compared to WT littermates (Fig. 
5.6D), irrespective of initial immunization with adjuvant only or with MOG and adjuvant. 
These data suggest that reduced ZAP70 phosphorylation and expression are features of 
TgsAPP-α mice after either naïve or recall immune challenge. This phenomenon may be 
involved in the T-cell memory-response impairment exhibited by splenocytes from these 
mice. 
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Figure 5.6: Impaired recall response in T-cells isolated from TgsAPP-α mice 
splenocytes may be influenced by ZAP-70. Transgenic mice and wild-type littermates at 16 
weeks of age were immunized with MOG/CFA/PTX or PBS/CFA/PTX (vehicle control). Splenocytes 
were isolated from mice 14 days after immunization, cultured in 24-well plates at 5 x 106 cells per 
well, and challenged with PBS, 5ug/ml ConA or 10ug/ml MOG for 36 h. Supernatants were 
collected and cell lysates prepared from these splenocyte cultures. (A, B) Cytokines secreted by 
each of the cultures into supernatants were measured by ELISA. Results displayed as mean ± 
standard error in ng or pg per mg of total protein. (C) Cell lysates were probed for Syk-family 
protein tyrosine kinase ZAP-70. (D) The ratio of phospho- to total ZAP-70 after densitometric 
analysis is shown here. 
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Conclusions 
By performing these experiments, we intended to identify any immunological 
features that could result from sAPP-α over-expression, in effort to comprehend how the 
APP fragment could be contributing to the pathophysiology of autism.  
We have shown increased secretion of pro-inflammatory cytokines IL-2, IL-4 and 
IFN-γ after T-cell mitogen stimulation of TgsAPP-α splenocytes. Splenocyte populations 
from TgsAPP-α mice consisted of decreased B-cell and increased T-cell sub-populations. 
Further investigation of developing T-cells from TgsAPP-α mouse thymus produced 
varying population sizes of mature and immature thymocytes, in comparison to WT 
littermates, though patterns of population sizes remained the same. We discovered that 
apoptosis is reduced in TgsAPP-α mouse thymocytes, which plausibly demonstrate 
increases in anti-apoptotic and decreases in pro-apoptotic signaling proteins. Finally, 
splenocytes from TgsAPP-α mice immunized with MOG exhibited an impaired recall 
response to in vitro MOG challenge and showed reduced levels of phosphorylated ZAP-
70 in TgsAPP-α mice, irrespective of immune challenge. 
Overall these findings imply that sAPP-α over-expression alters both the 
development and function of T-lymphocytes, thereby contributing to autism 
pathophysiology. 
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CHAPTER 6: DISCUSSION – Conclusions, Limitations and Implications 
 
Over-expression of sAPP-α in autism patients 
 According to an initial study performed on plasma samples, autism patients 
exhibit elevated levels of the sAPP-α fragment compared to age-matched, normally-
developed children [171]. This study was the first to suggest an association between 
APP, a fundamental component of the amyloid plaques characteristic of Alzheimer’s 
disease, and autism, a heterogeneous neurodevelopmental disorder with unknown 
etiology. Also, the gene encoding the APP-binding protein, APB2, is considered an 
autism candidate gene [307, 24]. However, this association is novel and has not yet 
been widely accepted. To explore this association, our team obtained plasma samples 
from autistic patients and typically-developed controls aged 2 - 5 years, and measured 
sAPP-α concentrations by ELISA and Western blot. Our results showed that children with 
autism do express elevated levels of sAPP-α compared to normally-developed controls 
(Fig. 3.1). These data corroborated the findings of the previously mentioned Sokol study. 
Moreover, a later study further substantiated this finding, reporting that the plasma 
samples from a larger group of autism patients exhibit elevated levels of the APP 
fragment compared to normally developed children [308].  
 Given that the sAPP-α fragment is a known neurotrophic factor [188], and 
considering preliminary immunohistochemistry data indicating the presence of “N-
terminal truncated” amyloid-β in autistic patient neurons (data was later published 
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[246]), we thought to investigate the levels of sAPP-α in the brains of autism patients. 
To do this, we obtained frozen brain specimens from the insular cortex region of 
patients diagnosed with autism and normally developed children, and measured sAPP-α 
levels in homogenates from these brains using ELISA. This experiment revealed 
elevations of sAPP-α in the brains from autistic patients. In addition, we used Western 
blot to investigate the levels of α-CTF in these patients and controls, since non-
amyloidogenic processing of APP, which generates the sAPP-α fragment, also produces 
α-CTF. Autistic patient brain homogenates contained greater levels of α-CTF compared 
to homogenates from control children (Fig 3.2). Together, these data provide initial 
evidence for the existence of increased sAPP-α in the brains of children with autism; 
such existence is likely due to an up-regulation of the non-amyloidogenic processing 
pathway. 
Another neurotrophic factor commonly found at altered levels in autistic patient 
sera is brain-derived neurotrophic factor (BDNF). It is believed that BDNF plays a role in 
autism pathogenesis, possibly through the serotonergic system [309]. In some studies, 
elevations in BDNF and BDNF autoantibodies in autistic patient sera suggest an 
interaction between BDNF and the immune system that may contribute to autism 
pathophysiology [310-313]. On the contrary, there is evidence of reduced BDNF release 
from the platelets of 0 – 9 year old autistic individuals compared to teenagers and 
controls, indicating a delayed increase with ongoing development [314]. One study 
reports that both BDNF and sAPP-α require telomerase for their cell survival-promoting 
actions in early postmitotic hippocampal neurons [315]. BDNF was considered for a 
biomarker of autism, but a study showing no significant difference in BDNF 
concentrations from maternal or newborn blood specimens from autistic, intellectually 
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disabled or typically-developed children concluded that it is likely not useful for this 
purpose [39]. Our group proposed sAPP-α as a peripheral biomarker for autism [172], 
but its use for this purpose is tentative as there is need for larger epidemiological 
studies strengthening the correlation between elevated sAPP-α in umbilical cord blood 
and/or plasma and autism diagnoses. 
The data outlined in Chapter 3 augment the evidence supporting the link 
between sAPP-α and autism. This connection may be explained by the previously 
proposed notion of an increase in non-amyloidogenic processing in autistic patients [171, 
308]. Additionally, the existence of “N-terminal truncated Aβ” undoubtedly denotes 
cleavage of APP by the α-secretase enzyme that generates the sAPP-α and α-CTF 
fragments, thereby further supporting the proffered concept. It is worth noting that the 
up-regulated pathway in autism is contrary to the pathway up-regulated in 
neurodegenerative Alzheimer’s disease. Given that autism disorder is 
neurodevelopmental in nature, and the non-amyloidogenic pathway is anabolic, it stands 
to reason that up-regulation of this pathway could contribute to the neurobiological 
features observed in autism patients. Recall that such features include rapid brain 
overgrowth within the first 3 years of life [81, 54], macrocephaly [44] increased neuron 
numbers [75] and size [70], all of which could be attributed to increased neurotrophic 
factor function.  
In a similar line of interest, APP is linked to the most commonly inherited form of 
intellectual disability which is frequently a comorbidity of autism, Fragile X Syndrome 
(FXS) [316]. In one study, scientists showed that the over-expression of APP in fmr1-
knockout mice increases mortality and susceptibility to seizures, a common comorbidity 
of autism [317]. Another study reports that fragile X mental retardation protein (FMRP) 
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protein binds to and regulates the translation of APP mRNA in murine resting 
synaptoneurosomes through metabotropic glutamate receptor (mGluR5) activation [318]. 
According to one theory, FMRP and neurotrophic sAPP-α are part of a process that 
regulates nervous system development; reduction of FMRP favors increased sAPP-α 
which causes the symptoms of FXS and autism [308]. This hypothesis is certainly 
feasible, but does not consider the possible contribution of sAPP-α in its immunological 
role. 
 
Effects of sAPP-α overexpression on behavior 
In spite of the above speculations, the role of APP, let alone, the sAPP-α 
fragment in autism spectrum disorders is yet to be well-established. The association 
between the sAPP-α fragment and autism spectrum disorders along with the well-
documented functions of sAPP-α as a neurotrophic and neuroprotective factor led us to 
investigate how sAPP-α could be impacting the brain, thereby leading to behaviors 
characteristic of the autism phenotype. We designed a transgenic mouse that 
overexpresses human sAPP-α in the brain and other organs, as dictated by a leaky 
murine prion protein promoter. In addition to biochemical assays used to appraise the 
successful generation of TgsAPP-α mice, we performed behavioral tests to assess 
activity, anxiety, cognition and social interaction in these mice. 
As described in Chapter 4, our data confirm that we generated a transgenic 
mouse that over-expresses hsAPP-α in the brain and plasma. The mice therefore mimic 
the elevated levels of sAPP-α we observed in both plasma and brain of autistic patients 
(Fig 4.1 and 4.2). In light of the unknown etiology and the heterogeneity of autism, 
mouse models of autism recapitulate specific genetic or environmental candidate causes 
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for the disorder and examine autistic-like behavior in the mice using behavior tests with 
face validity in mice for cardinal autistic behaviors and common co-morbidities of autism 
[319, 140]. While we hesitate to call the TgsAPP-α mice a mouse model of autism, we 
acknowledge that we imitated the biochemical elevations of sAPP-α seen in patients with 
autism and have used the similar behavioral tests to assess autistic-like behaviors in the 
mice. Behavioral analyses of TgsAPP-α mice produced no signs of anxiety (Fig 4.3a and 
4.4), motor imbalance, lack of coordination (Fig 4.5) or cognitive impairment (Fig 4.6 
and 4.7) in these mice compared to WT littermate controls. However, TgsAPP-α mice 
displayed hypoactivity in the open field task (Fig 4.3b), and male TgsAPP-α mice 
exhibited decreased preference for social interaction (Fig 4.8).  
Social behaviors in mice involve the use of visual, olfactory and tactile faculties. 
The behavioral task used to measure sociability in transgenic mice and controls in our 
experiments provides a simple, standardized method of assessment of time spent with 
an unfamiliar mouse. It does not closely observe or score the senses employed in 
socialization in the animals. Sniffing in particular is assessed during many other tests 
measuring sociability in mice, however the designers of the sociability test we employ 
have found that sniffing of the wire cage (whether or not it contains a stimulus mouse) 
correlates significantly with time spent in that chamber, suggesting that time spent in 
the chamber is an accurate representation of social approach in the mice [320]. The 
results of our own social interaction experiments produced a close correlation between 
sniffing and time spent in a particular chamber (data not shown). Therefore we also 
conclude time spent in the chamber is a sound measure of social approach.  
Among the neurobiological structures involved in human social cognition are the 
neocortex, amygdala, prefrontal and somatosensory cortices and the hypothalamus 
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[321]. Damage to the frontal lobes of the brain during early development leads to more 
severely impaired moral knowledge in comparison to similar damage during adulthood 
[322]. Also, oxytocin, vasopressin [323, 324], and serotonin [260, 325, 326] are linked 
to social behavior based on studies resulting in social impairment in humans and animal 
models due to abnormalities in these neurochemical systems. While we did not pay 
attention to brain peptide or hormonal systems, we performed neurobiological 
experiments on TgsAPP-α mice focusing on cortical regions of the brain and including 
the hippocampus. Given that sAPP-α is neurotrophic, these experiments involved 
observations of gross neuronal numbers and morphology. We were unsuccessful in 
revealing any significant changes in these features as a result of sAPP-α over-expression 
in our model. However, we did reveal an increase in synaptophysin expression in 
postnatal TgsAPP-α mice (Fig 4.9), suggesting a sAPP-α-induced increase in synaptic 
density at that stage of brain development. This finding substantiates the neurotrophic 
effects of sAPP-α on synaptic density [190]. 
One possible explanation for the absence of neuron number or morphology 
alterations is that sAPP-α does not directly affect cell fate or shaping of neural precursor 
cells during development, which would lead to increased neuronal numbers. On another 
note, given that neuronal sAPP-α release is activity-dependent [183, 184] the 
abundance of hsAPP-α being secreted without a need for α-secretase processing in the 
brain may be affecting its neurotrophic function in vivo.  
 
Immunological aberrations due to sAPP-α over-expression 
 Several studies implicate the sAPP-α fragment in the initiation of T-cell activation 
[225, 224]. We additionally thought to look at immune abnormalities in TgsAPP-α mice, 
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since autistic patients exhibit aberrant immunological features such as elevated pro-
inflammatory cytokine levels [102, 105], and alterations in T-cell populations  and 
function [125, 123, 121].   
 Measurements of cytokines released from TgsAPP-α splenocytes that were 
challenged with a T-cell mitogen revealed increased secretion of cytokines IL-2, IL-4 and 
IFN-γ, with no change in IL-6, IL-1β or TNF-α secretion (Fig 5.1). The effect of sAPP-α 
on T-cell cytokine release is worth noting given that cytokines cross the blood-brain 
barrier (BBB) [95] and can affect neuron development and function [97]. All of these 
cytokines have been assayed in autism patient plasma, but the reports conflict with each 
other. For example, one study reports no change in IL-6, TNF-α or IFN-γ in plasma 
samples from autistic patients [327] while a couple of other studies reveal increases in 
plasma levels of IFN-γ [328, 329]. An in vitro study demonstrates that there are intra-
cellular increases in IL-4, but decreases in IFN-γ and IL-2 in CD4+ and CD8+ T-cells from 
autistic patients following stimulation [123]. Yet another in vitro study revealed 
increased release of TNF-α and IL-1β from peripheral mononuclear blood leukocytes 
(PMBLs) from autistic patients stimulated with LPS [102]. While our cytokine secretion 
results did not exactly match the in vitro data obtained from autism patient plasma 
samples, they do suggest abnormality in T-cell cytokine secretion due to the over-
expression of sAPP-α. Our results also imply that sAPP-α may contribute to the altered 
secretion patterns observed by impacting either T-cell development, leading to the 
production of more T-cells, or T-cell function, whereby existing T-cell numbers secrete 
greater levels of cytokines.  
Our investigation of the B- and T-cell populations in TgsAPP-α mouse splenocytes 
revealed an increase in the T-cell population (Fig 5.2) and a closer look at their 
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thymocytes showed alterations in the sizes of the different sub-populations of mature 
and immature T-cells (Fig 5.3). These alterations in population sizes may be explained 
by a reduction in apoptosis and apoptotic signaling in the thymus, which according to 
our data, is evident. We found reduced caspase 3 expression, decreased TUNEL staining 
in TgsAPP-α mice compared to WT littermates (Fig 5.4), as well as increases in anti-
apoptotic proteins Bcl-2, NICD and p-PI3K in conjunction with decreases in pro-apoptotic 
Bax, and caspase 3 (Fig 5.5). While B-cell numbers appear unaffected in autism patients 
[116], T-cell populations and sub-populations studied are varied. It is worth noting that 
these lymphocyte populations are studied in plasma, and not in patient biopsies from 
thymus or spleen. We did not examine peripheral lymphocytes from TgsAPP-α mice 
because measures of the lymphocyte populations within the immune organs we 
investigated were more technically feasible. In spite of this limitation, our findings offer 
a potential role for sAPP-α in the altered cellular immunity features observed in autism 
patients, particularly pertaining to T-cell population. For example, our results showed a 
decrease in CD4+ T-cells in TgsAPP-α mouse splenocytes, and this corresponds to a 
decrease in circulating CD4+ T-cell populations in autism patients [94, 119]. Another 
case in point occurs with our findings of impaired recall response, discussed later. 
Experimental evidence of deranged apoptosis in autistic patients has been 
demonstrated in the brain [330, 331], but not in immune organs to date. The relevance 
of the finding that sAPP-α over-expression in thymocytes leads to a reduction in 
thymocyte apoptosis may extrapolate to brain cells, given that sAPP-α also promotes 
neuron survival. Therefore in patients, for example, elevated sAPP-α levels may 
contribute to characteristic neurobiological features such as macrocephaly and increased 
neuron numbers by reducing neuronal apoptosis during the natural period of neuronal 
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and synaptic pruning. Although our model did not demonstrate such neurobiological 
abnormalities, the idea may be proven fact in other models.  Many different pathways 
are implicated in the mechanism by which sAPP-α exerts its neuroprotective effects [216, 
215, 214], however the PI3K pathway and the Bcl-2 family of proteins are only indirectly 
associated with non-amyloidogenic APP processing in experiments examining neuron 
survival [208, 332]. Indeed, it is probable that sAPP-α performs its anti-apoptotic 
functions using multiple pathways.  
 We further discovered that splenocytes from MOG-immunized TgsAPP-α mice 
exhibit an impaired recall response as demonstrated by reduced IFN-γ, IL-2 and IL-4 
release after in vitro MOG challenge (Fig 5.6b). Plausibly, however, splenocytes from 
MOG-immunized TgsAPP-α mice secreted increased levels of these three cytokines after 
ConA challenge (Fig 5.6a), as was expected based on our previous experiment (Fig 5.1). 
Together, these results imply that sAPP-α adversely and specifically affect the memory 
function in lymphocytes, thereby debilitating the adaptive immune response. Here is the 
other case in point suggesting a probable contribution of sAPP-α to the altered cellular 
immunity features observed in autism. Studies on peripheral mononuclear blood 
leukocytes (PMBLs) from autistic patient plasma have shown depressed T-lymphocyte 
responses to mitogens [119, 115] corroborating an adverse effect for sAPP-α over-
expression in T-cell function as well as population numbers. 
The ZAP-70 kinase, which is critical for the initiation of T-cell activation, was also 
studied in these splenocytes from MOG-immunized TgsAPP-α mice. Through these 
experiments, we observed reductions in the ratio of p-ZAP-70 to total ZAP-70 in TgsAPP-
α mouse splenocytes, regardless of the type of immune stimulation, which hints at a role 
for sAPP-α in ZAP-70 phosphorylation (Fig. 5.6C & D). There must be another 
80 
 
mechanism that is affected by sAPP-α over-expression causing impaired T-cell memory, 
which may act in addition to the already resultant decrease in pZAP-70 already. Also, 
the general pZAP-70 reduction in splenocytes with sAPP-α over-expression may explain 
the deviation in the activation profile of T-cells from TgsAPP-α mice. Recall that these 
mice do not express increases in IL-6, TNF-α and IL-1β, which is expected under pro-
inflammatory conditions. 
There is strong evidence for the activity of ZAP-70 in T-cell development as well. 
Studies suggest that the kinase plays an essential role in positive and negative selection 
of thymocytes during T-cell development [333]. According to one study, ZAP-70-/- mice 
lack CD4+ and CD8+ T-cell populations which were reconstituted with the addition of 
human ZAP-70 [334]. ZAP-70 is phosphorylated before downstream signaling initially 
triggered by the T-cell receptor complex, which is required for testing T-cell function for 
survival or elimination during positive and negative selection, [297]. We did not look at 
phosphorylated ZAP-70 expression in TgsAPP-α mouse thymocytes because our focus 
was on explaining the reduced recall response in splenocytes. However, the reduction in 
the ratio of pZAP-70 to total ZAP-70 in TgsAPP-α mice irrespective of immune challenge 
may also explain the unusual T-cell and thymocyte populations observed in these mice 
(Fig 5.3).  
A genome-wide methylation profile of blood cells from patients with chronic 
lymphocytic leukemia (CLL) showed that increased APP gene methylation is associated 
with ZAP-70 expression, which is a prognostic factor for CLL [335]. This is the only study 
in the literature associating APP with ZAP-70 expression. DNA methylation suppresses 
gene transcription and is crucial for the development of most types of cancer [336], but 
the role of the APP gene in CLL is unknown [335]. Therefore, further studies are 
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required to identify the mechanism by which sAPP-α may be affecting ZAP-70 
phosphorylation. 
 Altogether the immunological findings from the TgsAPP-α mice substantiate the 
theory that sAPP-α is involved with the T-cell response and provides a theory for the 
correlation and possible association between elevated levels of sAPP-α and aberrant T-
cell immunity in autism [337].  
 
Overall Conclusions and Future Direction 
In closing, we have made attempts to identify the potential contributions of 
sAPP-α to autism pathophysiology. Altogether, we have shown that sAPP-α is found at 
elevated levels in autism patient plasma and brain, and that sAPP-α over-expression in a 
mouse produces hypoactivity, decreased preference for sociability in males, increased 
synaptic density and aberrations in T-cell development and function. These findings 
support the association of APP with autism and, additionally, propose a method by which 
sAPP-α affects T-cell populations and activation. In addition to being a potential 
therapeutic target that would address aberrations in two separate mammalian systems 
within the patient, sAPP-α may also be a potential biomarker for a subset of patients 
with autism spectrum disorder.  
It is of note that, as of yet, there is no epidemiological evidence to verify that 
autism patients demonstrating elevations of sAPP-α in the brain and plasma also exhibit 
abnormalities in immune cell populations and function. While these studies remain to be 
performed, we propose, in light of our findings and others previously reported, that 
sAPP-α may operate by impacting the brain or the immune system to propagate the 
pathophysiology of autism. 
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The conclusions of these studies contribute to the idea that the immune system 
is very much involved in the maturing and ultimate functional output of the CNS. Our 
focus in these studies was the adaptive immune system, and more specifically the T-cell, 
given that sAPP-α is involved in T-cell activation in addition to its neurotrophic properties. 
However, recent evidence suggests that innate immunity plays vital roles in brain 
development and function as well [338, 339]. The brain’s resident immune cells, 
microglia, as well as monocytes and macrophages from the periphery, and complement 
are currently being studied to identify their distinct functions in neuronal processes. 
Synaptic pruning by microglia, for example, is shown to be necessary for normal brain 
development [340]. 
Taking into consideration all the information I have acquired working on this 
project, I believe that a large-scale solution to the problem of autism diagnosis and 
treatment lies in the contributions of the immune system to the maturation of the CNS. 
It is already well established that both genetics and the environment are involved in 
autism etiology, and mammalian immunity is essential in interactions between the body 
and invasive environmental components. Therefore I propose that studies be done 
focusing more on neuroimmune communication during pre- and postnatal CNS 
development as it pertains to the pathogenesis of neurodevelopmental disorders such as 
autism.  It is my desire to participate in such studies in the near future.  
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